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Chapter 1.1 Introduction and outline of thesis
Cancer is a leading cause of death in the Netherlands.  Every year over 100.000 Dutch people are 
diagnosed with cancer. Treatment options include surgery, radiotherapy and systemic therapies 
such as chemotherapy, immune therapy, endocrine therapy and targeted therapy. 
In this thesis the pathogenesis of adverse effects of angiogenesis inhibitors, a group of targeted 
agents, is studied. 
Angiogenesis is the formation of new capillaries from endothelial cells of existing vasculature. 
This is an essential physiological process in wound healing, embryogenesis and the female 
reproduction system. It is, however, also essential for tumor growth. When a tumor exceeds 
a few millimeters in size as a consequence of hypoxia and nutrient deprivation an imbalance 
develops in angiogenesis stimulator-  and inhibitor levels leading to an ‘angiogenic switch’1. 
This process of angiogenesis is regulated by several growth factors and receptors. Vascular 
endothelial growth factor (VEGF) and its receptors play a key role. VEGF, a 45 kDA glycoprotein, 
is mainly secreted from mesenchymal, stromal and epithelial sources to act on endothelial cells. 
The angiogenic effects of VEGF are primarily mediated by VEGFreceptor-2 (VEGFR-2)2. In the 
seventies of the past century Folkman already proposed angiogenesis inhibition as a strategy 
for the treatment of malignancies. Several decades of research followed and in 2004 the first 
angiogenesis inhibitor, bevacizumab,  was approved for the treatment of metastastic colon 
cancer in combination with chemotherapy3. 
Bevacizumab is an, intravenously administered, humanized monoclonal antibody directed 
against VEGF. It has been approved by the European Medicine Agency (EMA)  for the treatment 
of metastatic colon cancer, metastatic breast cancer, non-small cell lung cancer, advanced or 
metastatic renal cancer, metastatic ovarian cancer,metastatic cervical cancer and glioblastoma. 
Meanwhile several other drugs including small molecule receptor tyrosine kinase inhibitors such 
as sunitinib have been developed. Sunitinib is approved for the treatment of metastatic renal cell 
carcinoma, gastrointestinal stromal tumor (GIST) and neuro-endocrine tumors of the pancreas. 
Sunitinib not only targets the VEGF-receptor, but also the platelet derived growth factor (PDGFR), 
stem cell factor receptor (c-KIT) , FMS-like tyrosine kinase-3 (FLT-3), glial cell-line derived 
neurotrophic factor receptor (RET) and colony stimulating factor 1 receptor (CSF1R) [27-30].
At the introduction of angiogenesis inhibitors no major side effects were expected. Under 
normal circumstances more than 99% of endothelial cells do not replicate and in healthy adults 
angiogenesis only seems to play a role in wound healing and the menstrual cycle4,5. However 
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unfortunately various side effects did occur in patients. One of the most reported side effects 
of VEGF-targeted therapies is hypertension. Hypertension occurs in 19% to 80% of patients, 
depending on the used  definition of hypertension6-8. Even more patients experience a rise in 
blood pressure9. Several hypotheses for the pathogenesis of hypertension exist. First, it could 
be an effect on the endothelium as VEGF has been shown to induce synthesis or release of 
the vasodilator nitric oxide10 11. Inhibition of VEGF-signalling could result in a decrease in nitric 
oxide availability, which could lead to endothelial dysfunction, vasoconstriction and subsequent 
hypertension. Second, a possible effect on neurohumoral factors could be involved in the 
pathogenesis. Sunitinib has been shown to cause a rise in endothelin-1 after four weeks of 
treatment12. However no correlation between rise in blood pressure and endothelin-1 or other 
neurohumoral factors, such as aldosterone, renin or norepinephrine was reported. All clinical 
experiments into the pathogenesis of hypertension have been performed after several weeks 
of treatment, while the onset of  hypertension in patients treated with VEGF-inhibition is  usually 
within the first week. Thus, observed neurohumoral and endothelial changes could be a 
consequence rather than a cause of the rise in blood pressure. 
Moreover in the last years concerns have been raised about the development of heart failure, 
reduction in left ventricular ejection fraction (LVEF) and the occurrence of cardiac ischemic events 
during treatment with sunitinib and other VEGF-targeted therapies13-15. Hypertension, a history of 
chronic heart failure and coronary artery disease are defined as predictors for the development 
of heart failure in patients treated with sunitinib13,15,16.  Obesity, diabetes and insulin resistance are 
common in patients with renal cell carcinoma and are  risk factors for the development of cardiac 
failure and hypertension. In several animal studies VEGF is reported to be the most important 
angiogenic factor in adipogenesis17. Moreover in patients inhibition of VEGF is associated with 
changes in body composition independent of gastrointestinal side effects and a drop in glucose 
concentrations 18,19. These observations could be beneficial to patients, regarding the risk of 
cardiovascular events, however excessive weight loss and unexpected hypoglycaemic 
events are unwanted adverse events in the frail oncologic patient population. Looking beyond 
the boundaries of cancer treatment this effect on body composition and glucose levels are 
intriguing as they could be of interesting potential for the treatment of obesity or diabetes. 
Introduction
13
Aim and outline of this thesis
Drug-induced hypertension provides a unique opportunity to study the early phase of 
development of hypertension and cardiovascular toxicity. In this thesis, we describe a series of 
experiments focused on the early pathogenesis of cardiovascular and metabolic side effects of 
the VEGF-targeted therapies, bevacizumab and sunitinib, with the aim of providing insight into 
possible treatment or preventive strategies for patients experiencing these adverse effects and 
moreover to provide insight into the role of VEGF and other targeted growth factors in normal 
physiologic processes such as regulation of vascular tone. 
In chapter 2, based on the observation that patients treated with angiogenesis inhibitors 
with previous ischemic heart disease are at risk of developing heart failure,  we hypothesized 
that sunitinib may enhance cardiac vulnerability to ischemia which could contribute to the 
pathogenesis of sunitinib-associated heart failure. Therefore we exposed isolated human cardiac 
trabeculae to sunitinib and simulated ischemia and reperfusion in an in-vitro experiment. A better 
understanding of the pathogenesis of VEGFR inhibitors-related cardiotoxicity would allow  us to 
identify those individuals who are at increased risk for developing heart failure. 
In chapter 3, 4 and 5 we studied the pathogenesis of hypertension during treatment with 
angiogenesis inhibitors in animals, healthy volunteers and patients. In chapter 3 the direct 
effect of scavenging VEGF from the arterial circulation in healthy volunteers on endothelial 
function was studied by arterial infusion of bevacizumab in order to investigate the role of VEGF 
in normal vascular physiology. In chapter 4 a preclinical animal experiment was combined with 
a clinical study in metastastic renal cancer patients to study the effect on endothelial function 
after one week of sunitinib treatment. In chapter 5 the early changes in aldosterone, renin and 
endothelin-1 levels were measured in a metastatic renal cancer patient group within one week 
after start of sunitinib treatment. 
In chapter 6 and 7 we focus on the effect on body composition and glucose handling. Therefore 
in chapter 6 the literature on VEGF inhibition and the effect on body composition was reviewed 
and in chapter 7 the effect on insulin sensitivity and insulin clearance was studied by performing 
a hyperinsulinemic euglycemic clamp before and one week after start of sunitinib treatment in 
patients with metastatic renal cell carcinoma. 
In the chapter 8 the main findings and conclusions of the previous chapters are summarized 
and discussed and future perspectives are described. 
Introduction
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Chapter 1.2 Applied methods
1. Atrial tissue (chapter 2)
During cardiac surgery with extracorporal bypass surgery the right auricle is incised to allow insertion 
of the cannules for the extracorporeal circulation. Some surgeons excise the right auricle at this 
timepoint. Therefore it is an unique opportunity to harvest human atrial tissue without exposing 
patients to unwanted risks. Patients were asked for informed consent prior to surgery. The method 
was based on the method described by Speechly-Dick20.  After harvesting the atrial tissue it is 
immediately placed in a cold solution and transported to the laboratory. In the laboratory under 
magnification two atrial trabeculae are dissected and vertically suspended and linked to a force 
transducer in an organ bath (figure 1). Once suspended, trabeculae are paced by field stimulation 
at 1 Hz by platinum electrodes which start contraction of the trabeculae. The force transducer 
registers the amount of force, rate and speed of contractions. By increasing field stimulation to 3 
Hz and by changing the perfusate which passes through an artificial lung from an oxygen-  and 
nutrition rich to oxygen- and nutrition deprived solution periods of ischemia and reperfusion can be 
simulated. Both trabeculae are suspended in a different organ bath, allowing the separate infusion 
of placebo or investigational product, but with the same conditions regarding the source of the 
tissue, perfusate and pacing allowing controlled and paired experiments.
FIGURE 1 
Atrial trabeculae suspended in organ bath
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2. Venous occlusion plethysmography (chapter 3 and 4)
Venous occlusion plethysmography is a well validated technique to measure forearm blood 
flow (FBF) and the local vasomotor responses to the administration of drugs into the brachial 
artery. By recording  the vasodilator response to an endothelium-dependent vasodilator, such 
as acetylcholine, and an endothelium-independent vasodilator, such as the nitric-oxide donor 
nitroprusside,  we are able to assess endothelium-mediated vasodilation.  Administration of 
drugs into the brachial artery results in high local concentrations in the forearm vascular bed, 
however after venous return into the systemic circulation, concentrations decrease because of 
the large volume of distribution and metabolism. Therefore there is only low systemic exposure 
to infused drugs preventing confounding systemic effects and reducing the chance of toxic side 
effects. The subject is placed on a bed and a wrist cuff, an upperarm cuff and a mercury-filled 
silastic strain gauge are applied to both arms (Figure 2). Inflation of the upper arm cuff to 40 
mmHg during 6-10 heartbeats allows for unhindered arterial inflow but hampers venous return. 
The pooling of venous blood results in swelling of the forearm. The increase in diameter can 
be measured by the mercury-in-silastic strain gauges and the rate of this increase represents 
FBF. Forearm blood flow, under stable blood pressure, reflects the vascular tone in resistance 
vessels. The skin circulation of the hand is excluded, by inflation of the wrist cuff to 200mmHg, 
to restrict blood flow measurement to the skeletal muscle vascular bed as much as possible. 
Forearm blood flow is measured simultaneously in the experimental and non-experimental arm. 
Endothelium function can be assessed by measuring changes in FBF in response to the 
infusion of different dosages of vasoactive substances.  In the studies in healthy volunteers 
(chapter 3) we used 20 gauge arterial catheters to allow the measurement of arterial blood 
pressure for continuous check of the intra-arterial catheter position and for the detection of any 
relevant systemic effects. Furthermore, simultaneous measurement of arterial blood pressure 
allows for estimation of changes in forearm perfusion pressure and subsequent calculation of 
changes in vascular resistance. In the metastatic renal cancer patients (chapter 4) we used a 
smaller 27-gauge needle, without the possibility to measure arterial blood pressure, to prevent 
complications such as bleeding or thrombosis. Instead of forearm vascular resistance,  the ratio 
of simultaneously measured FBF in experimental and non-experimental arm (FBF-ratio)was 
calculated in this study.
Introduction
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Introduction
FIGURE 2 
Venous occlusion plethysmography
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3. Wire myograph (chapter 4)
The myograph was first described by Mulvany and Halpern (1976). It provides a method to 
research the vasomotor properties of small proximal resistance arteries (100-400µm). Resistance 
vessels play a major role in the development of hypertension, as they regulate the peripheral 
vascular resistance.  In this experiment rats are treated with placebo or sunitinib for one week and 
are subsequently euthanized. Post mortem, the intestine and mesenteric vessels are obtained 
from the rat and placed in a physiological salt solution.  Small resistance arteries are cleared of 
other tissue (mainly fat) and dissected. The segment is placed on a 40 mm wire and attached to 
a mounting jaw of the Mulvany myograph in an organ bath. Then a second wire is inserted and 
attached to a second mounting jaw (Figure 3).  From each rat 4 arteries are obtained and placed 
in pairs in 2 myographs. After normalization and equilibration different vasoactive substances 
can be added to the organ bath to measure the effect on the mounted vessels. The wires inside 
the vessels are connected to a transducer which can record the changes in contractile force of 
vascular smooth muscle cells.
Introduction
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4. Hyperinsulinemic euglycemic clamp (chapter 7)
The hyperinsulinemic euglycemic clamp, developed by deFronzo et al in 1979, is the gold 
standard for assessing insulin resistance in humans. After an overnight fast patients are placed 
on a bed. Two intravenous catheters are introduced. One is positioned in an anticubital vein 
for the infusion of insulin and glucose and the other is inserted in a dorsal vein of the hand 
of  the opposite arm  for blood glucose sampling. This hand is placed in a heated box, which 
opens arteriovenous shunts, reducing differences in glucose concentration between venous and 
arterial blood. Insulin is infused at a steady state throughout the entire experiment. After the 
start of the experiment blood glucose is sampled every 5 minutes. Depending on the blood 
glucose concentration the glucose infusion is adapted to reach a steady state concentration of 
blood glucose after 120 minutes. This method assumes that high doses of insulin will completely 
suppress hepatic glucose and pancreatic insulin production and that there is no change in blood 
glucose concentrations under steady-state conditions. Thereby the rate of glucose infusion is 
equal to the whole-body glucose utilization. This allows calculation of the insulin sensitivity index 
by dividing the glucose infusion rate by the steady state plasma insulin concentration. 
Introduction
FIGURE 4 
Schematic view of the hyperinsulinemic euglycemic clamp
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CHAPTER 2
Sunitinib does not attenuate contractile force following  
a period of ischemia in isolated human cardiac muscle
Targeted oncology 2015; 10(3):439-43
A.M.J. Thijs, S. El Messaoudi, J.C.M. Vos,  A.C. Wouterse , V. Verweij, H. van Swieten, 
C.M.L. van Herpen, W.T.A. van der Graaf, L. Noyez, G.A. Rongen
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Abstract
Aim
Concerns have been raised about the development of heart failure in patients treated for cancer 
with angiogenesis inhibitors, such as the tyrosine kinase inhibitor sunitinib. Patients with previous 
coronary artery disease and hypertension have an increased risk of developing heart failure. 
Therefore we studied the effect of sunitinib on the contractility of isolated human atrial trabeculae 
and  the effect on recovery after ischemic stimulation. 
Methods
After informed consent the atrial appendage of patients undergoing cardiac surgery was 
harvested and isolated trabeculae were placed in an organ bath with a force transducer. During 
electrical stimulation contractile force was measured during normal pacing or  after simulated 
ischemia. Of each patient one trabecula was perfused with solvent and one with sunitinib. 
Results
Contractile force (expressed as percentage of baseline force) declined over time to 57±8% and 
73±20% after 150 minutes of stimulation for solvent and sunitinib treated trabeculae respectively 
(mean ± SE; n=8; p>0.1, ). After simulated ischemia and reperfusion, contractile force  was 
40±6% in the control compared to 39±6% in the sunitinib treated trabeculae during the last final 
5 minutes of reperfusion (n=12; p>0.1). 
Conclusion
Sunitinib at low, but clinically relevant,  concentrations does not have a direct effect on function 
of human atrial cardiomyocytes nor does it attenuate the recovery in contractile force of atrial 
cardiomyocytes  after a period of ischemia. A direct and acute toxic effect on cardiomyocytes 
does not explain the development of heart failure in patients treated with sunitinib. 
Cardiac effects of angiogenesis inhibitors 
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Introduction
Tyrosine kinase inhibitors (TKIs) are widely used in the treatment of cancer. Sunitinib, one of 
the most used angiogenesis inhibitors, is a multitargeted receptor TKI which is registered for 
the treatment of patients with metastatic renal-cell carcinoma (mRCC), gastrointestinal stromal 
tumors (GIST) and pancreatic neuroendocrine tumors.
Concerns have been raised about the development of heart failure, reduction in left ventricular 
ejection fraction (LVEF) and the occurrence of cardiovascular events during treatment with 
sunitinib and other vascular endothelial growth factor (VEGF)-targeted therapies1-3. In a recent 
meta-analysis of 5638 mRCC patients in 14 phase II-III trials with sunitinib the incidence of a 
heart failure was 3.6% 4. In most phase I-III trials however patients with cardiovascular risk factors 
such as coronary artery disease (CAD) and patients with an older age are excluded.  Therefore, 
these trials likely underestimate the real-life  incidence of cardiotoxicity since these exclusion 
criteria are generally not taken into account in the daily  clinical practice.  Furthermore, it is 
questionable whether heart failure is always recognized in cancer patients with dyspnea and 
fatigue who present with several oncological pulmonary and general conditions.
In the few studies, observational or retrospective, which do not exclude patients with cardiovascular 
risk factors, an increased incidence of cardiac events, up to 33.8% in mRCC patients, is reported5,6. 
Hypertension, a history of CHF and CAD are defined as predictors for the development of heart 
failure in patients treated with sunitinib1,3,7.  Chu et al describe that in a phase I/II study 75% of GIST 
patients with a history of CAD suffered a cardiovascular event versus 7% of those without CAD1. 
A better understanding of the pathogenesis of sunitinib-related cardiotoxicity would  allow  us to 
identify those individuals who are at increased risk for developing heart failure.  Ideally this would 
be followed by the design of therapeutic or preventive interventions for this condition.
The exact mechanism of sunitinib induced cardiotoxicity is not known. It has been suggested 
that sunitinib-related cardiotoxicity may involve pathways different from VEGF8,9 . In vitro studies 
show direct toxicity of sunitinib in cardiomyocytes  and on contractile force in human atrial 
trabeculae, however this effect was observed at very high concentrations, up  to 100- fold higher 
than therapeutic levels reached in plasma of patients 1,9,10. 
In patients who developed heart failure during treatment with sunitinib, structural and functional 
abnormalities are seen in the mitochondria of cardiomyocytes1,9.  Moreover, in vitro, sunitinib 
inhibits AMPK, an important kinase in maintaining metabolic homeostasis in the heart 9. Based on 
Cardiac effects of angiogenesis inhibitors 
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these studies and the observation that patients with previous CAD are at risk of developing heart 
failure  we hypothesized that sunitinib may enhance cardiac vulnerability to ischemia which could 
contribute to the pathogenesis of sunitinib-associated heart failure. To explore this hypothesis we 
initiated a study on the ex-vivo effect of sunitinib on contractility of human cardiomyocytes at a 
clinically relevant sunitinib concentration, and moreover deprived atrial trabeculae from  energy 
substrates (simulated ischemia) to investigate whether sunitinib-treated trabeculae attenuate 
contractile recovery after ischemia.
 
Methods
Patients
After approval of the protocol by the Institutional Review Board of the Radboud university 
medical center and prospective registration at www.clinicaltrials.gov (NCT01246778) 95 patients 
awaiting coronary artery bypass graft (CABG) and/or aorta valve replacement (AVR) agreed to 
participate. Written informed consent was obtained from all participants. 
Patients with atrial arrhythmias, right ventricular failure, atrial enlargement or patients treated with 
theophylline, oral antiarrhythmics or sulphonylureas were excluded because these drugs may 
interfere with ischemia reperfusion outcome.
General experimental set up
The experimental set-up modified from Speechly-Dick et al as described by Riksen et al was 
used 11,12. The right atrial appendage was harvested during cardiac surgery at the right atrial 
cannula insertion site before the introduction of the extracorporal circulation and immediately 
placed in cold modified Tyrode’s solution (Nacl 118.5 mmol/l; KCl 4,8 mmol/l; NaHCO3 24.8 
mmol/l; KH2PO4 1,2 mmol/l; MgSO4 1,44 mmol/l; CaCl2 1,8 mmol/l; glucose 10,0 mmol/l and 
pyruvate 10,0 mmol/l) on ice, which was continuously gassed with 95% oxygen and 5% CO2. 
Two atrial trabeculae (diameter <1 mm; length >3 mm) were dissected, vertically suspended 
in an organ bath, and linked to a force transducer. Each trabecula was superfused with pre-
oxygenated Tyrode’s buffer (pO2 500 to 600 mm Hg). Electrical field stimulation was performed in 
unstretched condition at 1 Hz using platinum electrodes placed on both sides of the trabeculae 
(pulse duration 60 ms; pulse current 40 mA). After 30 min of stimulation at unstretched conditions 
to allow recovery from transportation and preparation, trabeculae were gradually stretched 
over 10 min until optimal contractile force was achieved. At the end of 20 min of equilibration a 
baseline recording was performed during 5 minutes. Those trabeculae that failed to produce at 
least 0.2 g of developed force at start of equilibration were excluded (n=32).
Cardiac effects of angiogenesis inhibitors 
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For both experiments, sunitinib was extracted from clinically available sunitinib capsules (Pfizer, 
United Kingdom) by dissolving the content of capsules in DMSO. Final sunitinib concentration 
in superfusate was 32.4 ± 4.1 ng/ml (confirmed by LCMS in four random experiments included 
in this study). In patients the total plasma concentration of sunitinib and its active metabolite, 
including 90-95% protein binded drug , is 50 – 100 ng/ml. The active metabolite accounts for 
approximately 30% of plasma concentrations in patients. The concentration of DMSO in the 
organ bath did not exceed 0.01%.
Experiment 1: effect of sunitinib on contractility
Immediately after baseline recordings, for each patient (n = 8) the two trabeculae were randomly 
assigned to either DMSO (control) or sunitinib. Electrical field stimulation at 1 Hz was  applied  for 
the entire experiment of 150 minutes. 
Experiment 2: effect of sunitinib on contractility after ischemia reperfusion 
Immediately after baseline recordings for each patient (n = 12) the two trabeculae were randomly 
assigned to either DMSO (control) or  sunitinib. After 20 minutes of superfusion with sunitinib or 
control,  60 minutes of simulated ischemia was started, which was accomplished by superfusing 
the trabeculae with substrate free modified Tyrode’s solution (7.0 mM choline chloride substituted 
for glucose and pyruvate) and rapid pacing at 3 Hz. The superfusate was pumped into an artificial 
lung filled with 95% N2/5% CO2, which results in a low pO2 of 10 to 20 mm Hg. Subsequently both 
trabeculae were subjected to  100 min of simulated reperfusion (pacing at 1 Hz, oxygen and nutrient 
containing superfusate as described above), still in the presence of either sunitinib or control. 
Data recording and statistical analysis
 
All data are presented as mean ± SE. For each contraction of the trabeculae, we calculated developed 
force (difference between maximal tension during contraction and minimal tension during relaxation). 
This parameter was averaged for the last 5 minutes during equilibration (taken as baseline) and each 
subsequent 5-minute period. Data were expressed as percentage of baseline developed force. A 
paired Student’s t-test was used to compare control with sunitinib treated trabeculae during the last 
5 minutes of the protocol in both experiments. P<0.05 was considered significant.
2
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Results
There were no significant differences in baseline characteristics between the groups in experiment 
1 and 2 (table 1). In 52 patients atrial tissue was harvested; because of poor quality of trabeculae 
at start of the experiment 32 patients were excluded and therefore 20 patients were included in 
the analysis. 
TABLE 1 
 Patient characteristics
Variable Experiment 1 Experiment 2
Number 8 12
Females 3(37,5%) 3(25%)
Age (years) 62.6 62.1
Range (37-75) (40-77)
   
CABG 4 (50%) 6 (50%)
AVR 3 (37,5%) 6 (50%)
CABG+AVR 1 (12,5%)  
   
Medication   
Beta Blockers 7 6
ACE-inhibitors 3 5
AII-receptor antagonists 0 1
Ca-antagonists 1 3
Nitrate 4 4
Aspirin 6 7
Statin 5 6
Insulin 2 2
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Experiment 1: effect of sunitinib on contractility
Baseline contractile force did not differ between trabeculae that were subsequently treated 
with control or sunitinib (0.50±0.1g and 0.51±0.05g; p=0.9). Contractile force (expressed as 
percentage of baseline force) declined over time to 57±8% and 73±20% after 150 minutes 
of stimulation for control and sunitinib treated trabeculae respectively (figure 1; p>0.1 for 
comparison between control and sunitinib treated cardiac muscle). 
FIGURE 1 
Effect of sunitinib on baseline contractile force (experiment 1)
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Experiment 2: effect of sunitinib on contractile force recovery after ischemia
Baseline contractile force did not differ between control and sunitinib treated trabeculae 
(0.54±0.1g and 0.51±0,05g; p=0.8). Ischemia reduced contractile force to a similar extent in 
trabeculae treated with control or sunitinib
Recovery was  40±6% in the control group compared to 39±6% in the sunitinib group during the 
last final 5 minutes of reperfusion (p>0.1). 
2
Cardiac effects of angiogenesis inhibitors 
32
FIGURE 2 
 Course of contractile force during simulated ischemia and reperfusion for trabeculae treated  
with control or sunitinib
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Discussion
We studied the ex vivo effect of sunitinib on contractile force  of human atrial trabeculae. This study 
provides for the first time data on the effect of sunitinib on human atrial contractile recovery after 
ischemia-reperfusion. At clinically relevant concentrations sunitinib did not have a direct effect on 
the function of human atrial cardiomyocytes nor did it attenuate the recovery in contractile force after 
a period of ischemia. These observations suggest that other actions of sunitinib are responsible for 
the clinical association of sunitinib therapy with heart failure. 
In the literature, several mechanisms of sunitinib-induced heart failure have been proposed. These 
mechanisms can be divided in actions in the cardiomyocyte and actions on cardiac perfusion or 
hemodynamic loading conditions of the heart.  Since we only studied the effects of sunitinib on 
isolated cardiac tissue, this discussion will focus on actions of sunitinib in cardiomyocytes.
Preclinical studies have suggested a direct toxic effect of sunitinib on cardiomyocytes. Hasinoff 
et al showed a dose dependent (2-5µM) increase of lactate dehydrogenase released from rat 
cardiomoyocytes treated with sunitinib13,14. Sunitinib exposure (0,1µM and higher) of Guinea 
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pig cardiomyocytes resulted in dose-dependent decreases in spontaneous contraction rate15. 
Moreover a direct toxic effect of sunitinib on human atrial trabeculae was observed by Rainer 
et al10. However these effects were only observed with supra-therapeutic concentrations of 
sunitinib. At a therapeutically more relevant concentration, Rainer et al did not observe an effect 
of sunitinib on contractile force during 30 minutes of exposure. In our experiment we prolonged 
the exposure time to optimize the uptake of sunitinib into the tissue, but we could still not detect 
an effect of sunitinib on contractile force. 
Since clinical data suggest that cardiac ischemia increases the risk of sunitinib-induced heart 
failure 1,3,7, we hypothesized that sunitinib may aggrevate the consequences of ischemia-
reperfusion injury of cardiomyocytes. This hypothesis is supported by various animal studies. 
Sunitinib inhibits the AMP protein Kinase (AMPK) pathway 9,14. Moreover AMPK is known 
to have an important defensive role in cardiomyocytes against energy stress triggers16. 
It is also an important pathway to protect the heart against ischemia-reperfusion injury17. 
Apart from interference with the AMPK-pathway, sunitinib could reduce cardiomyocyte tolerance 
against ischemia-reperfusion injury by inhibiting PDGF- signaling 9. In preclinical studies deletion 
of the PDGFr-β gene from cardiomyocytes leads to heart failure after exposure to overload18. 
Moreover in rats, PDGF seems to protect the heart when exposed to ischemic injury19. 
Our study shows, however, that sunitinib did not aggravate the functional consequences of 
ischemia followed by reperfusion, questioning the clinical relevance of these pathways in the 
development of sunitinib-induced heart failure. 
Some limitations of our study should be mentioned. First, the onset of sunitinib induced heart 
failure is not very well studied and may vary between patients. Based on scarce retrospective data 
the time of onset of sunitinib-induced symptomatic heart failure differs from a mean of 22 days 
after initiation to a median time of 33.4 weeks1,20.  In our study we only studied short term cardiac 
exposure of sunitinib.  Therefore,  based on our results we cannot exclude that longtime exposure 
to sunitinib does alter contractile recovery after ischemia. A second limitation is the use of  atrial 
and not ventricular trabeculae. Hence we do not know whether ventricular cardiomyocytes may 
differ from atrial cardiomyocytes in their response to sunitinib. Third, we used sunitinib, but not its 
active metabolite, which could also play a role in development of cardiotoxicity. 
In conclusion, our study suggests that direct myocardial toxicity  is insufficient to explain sunitinib-
associated heart failure. Therefore a combination of factors, such as structural or functional 
changes of the coronary vasculature, systemic hypertension or renal toxicity deserve more 
attention as potential causes of heart failure and volume overload. 
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Further exploration of  the mechanisms of sunitinib-associated heart failure is essential for 
developing better strategies to prevent and treat angiogenesis-TKI induced heart failure, in 
particular since this class of drugs is increasingly used in frail and aged patients, who are at risk 
for developing heart failure.
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Abstract
Aim 
Angiogenesis inhibitors have remarkably improved the outcome of patients with several types of 
cancer. Hypertension is the most reported side effect of angiogenesis inhibitors interfering with 
vascular endothelial growth factor signaling. In this study, we test the hypothesis that circulating 
vascular endothelial growth factor at physiological concentrations is essential to preserve normal 
endothelial control of vasomotor tone.
Methods and results
In seven healthy male volunteers, infusion of  bevacizumab (monoclonal anti- vascular 
endothelial growth factor antibody) into the brachial artery for 15 minutes (144 µg/dl forearm 
volume/min) did not affect forearm vasodilator tone as measured with venous occlusion strain 
gauge plethysmography. In a separate group of twelve male volunteers, a similar bevacizumab 
infusion reduced the vasodilator response to two dosages of acetylcholine  from (mean±SE) 
440 ± 157% and 926 ± 252% to 169 ± 40% and 612± 154 % (p<0.05). Finally, in a third group 
of 12 volunteers,  bevacizumab did not alter the percentage increase in forearm blood flow 
during infusion of sodiumnitroprusside at dosages equipotent to acetylcholine. 
Conclusion 
Bevacizumab acutely and specifically reduced endothelium-mediated vasodilation at local 
concentrations that resemble plasma concentration after systemic exposure to bevacizumab. 
This observation suggests a physiological role for vascular endothelial growth factor in 
maintaining normal endothelial control of vasomotor tone. The role of the endothelium in the 
mechanism of bevacizumab-induced hypertension deserves further exploration.
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Introduction
 
Angiogenesis, the formation of new capillaries from endothelial cells from existing vasculature, 
is essential for tumor growth. When tumor size exceeds a few millimeters an ‘angiogenic switch’ 
occurs as a consequence of hypoxia and nutrient deprivation1. Subsequently various pro-
angiogenic factors are released by tumor cells to activate quiescent cells to promote vascular 
growth to the tumor. Vascular endothelial growth factor (VEGF) and its receptors play a key 
role in this process. However, also in normal physiology VEGF may play a role in vascular 
homoeostasis. 
VEGF is an angiogenic growth factor which is mainly secreted from mesenchymal, stromal 
and epithelial sources to act on endothelial cells.. The angiogenic effects of VEGF are primarily 
mediated by VEGFreceptor-2 (VEGFR-2)2. 
In 1971 Folkman proposed angiogenesis inhibition as an alternative strategy for the treatment 
of  malignancies1. Meanwhile several drugs that target angiogenesis in tumors have been 
developed, almost all of them directed to VEGF or its receptors. Bevacizumab (BVZ), a humanized 
monoclonal antibody selectively binding VEGF was the first VEGF inhibitor approved by the FDA. 
BVZ in combination with chemotherapy has been approved for the treatment of metastatic colon 
carcinoma, unresectable or metastatic non-small cell lung cancer and glioblastoma and in 
combination with  interferon alpha for metastatic renal cell carcinoma. 
BVZ is generally considered to be safe and well tolerated but can be accompanied by a variety of 
side effects. An increased incidence of hypertension (defined as a blood pressure over 150/100 
mmHg or a rise of 20 mm Hg in diastolic blood pressure) of up to 34% has been observed in 
BVZ-treated patients in clinical trials compared with up to 14% in those treated with standard 
therapy. The most serious reported adverse drug reactions are hemorrhage and arterial thrombo-
embolism in patients treated with BVZ in combination with chemotherapy3. The most frequently 
observed adverse drug reactions across clinical trials in patients receiving BVZ are hypertension, 
fatigue or asthenia, diarrhea and abdominal pain4.  
Pharmacological doses of VEGF stimulate endothelial nitric oxide (NO) formation in preclinical 
models 5-7 and reduces blood pressure in animals and humans8.  In mice,  inhibition of VEGFR-2 
rapidly increased blood pressure and reduced the expression of endothelial and neuronal 
NO synthases in the kidney. Moreover treatment with a NO antagonist abolished the effect of 
VEGFR-2 inhibition on blood pressure 2. It is tempting to speculate that anti-VEGF treatment will 
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reduce endothelial NO release as the mechanism of BVZ-induced hypertension. However, the 
role of exposure of endothelial cells to endogenous VEGF has never been studied in humans in-
vivo. Therefore, it is currently not known whether BVZ-treatment results in endothelial dysfunction.
Therefore, the aim of this study was to explore the effect of specific inactivation of  endogenous 
VEGF  by binding to its monoclonal antibody BVZ on baseline vasomotor tone  and on 
endothelium-dependent vasodilation in humans in-vivo. 
 
Materials and methods
Subjects
After approval of the protocols (NCT00929058, NCT01125943) by the Institutional Review Board 
of the Radboud University Nijmegen Medical Centre, a total of 31 healthy nonsmoking male 
volunteers were recruited after written informed consent. Female subjects were excluded to 
prevent the influence of menstrual cycle and related hormonal changes on vascular reactivity. 
Subjects were eligible if they had no clinical history of hypertension, hyperlipidemia, renal 
dysfunction or diabetes mellitus. On specific request from our institutional ethical review board, 
subjects at increased risk for malignancy (first-degree relatives with cancer presented before 
age of 50 years) and  subjects with first degree relatives with premature atherosclerotic disease 
or recurrent (venous and/or arterial) thrombosis were excluded. All studies were performed 
according to institutional and Good Clinical Practice guidelines.
Study Design
General outline of the procedures
The experiments were performed after at least 24 hours of caffeine abstinence, in the morning after 
an overnight fast. Volunteers were studied in supine position in a temperature-controlled room 
(23±1ºC). At the start of each experiment a 20-gauge cannule (Angiocath; Becton Dickinson, 
Sandy, UT) was inserted into the brachial artery of the non-dominant arm for intra-arterial blood 
pressure measurement (Hewlett Packard, Böblingen, Germany) and infusion of drugs. 
During intra-arterial infusion of saline (NaCl 0.9%) or drugs forearm blood flow (FBF) was 
measured at both arms simultaneously, using electrocardiogram-triggered venous occlusion 
mercury-in-silastic strain-gauge plethymography (Hokanson EC4, Hokanson, Inc). During all 
forearm blood flow (FBF)  recordings  the hand circulation was completely occluded using wrist 
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cuffs inflated to 200 mmHg.  At least 30 minutes after the cannulation experiments were started. 
Drugs or solvent (either saline 0.9% or glucose 5%) were infused at a constant rate of 50 µl/dl 
forearm/ min. 
In all three studies BVZ (Avastin, Roche, the Netherlands) was infused intra-arterially to separate 
direct local effects of VEGF inhibition from systemic actions, such as hypertension, that could 
indirectly interfere with endothelial function. The normally prescribed intravenous dosage for 
BVZ ranges from 5 mg/kg to 15 mg/kg once every two/three weeks. For our studies we aimed to 
achieve a local BVZ concentration that occurs systemically after an intravenous  dose of 5 mg/
kg. In a pharmacokinetic study after first administration of  5 mg/kg BVZ mean observed Cmax 
was 123.2 µg/ml9.
Acetylcholine (ACH,  Miochol, 20 mg dry powder, dissolved to its final concentration with 
saline 0.9%, Novartis, Greece) and nitroprusside (SNP, 50 mg dry powder, Spruyt Hillen, the 
Netherlands (dissolved to its final concentration with 5% glucose solution; Clinical Pharmacy, 
Radboud University Nijmegen Medical Centre) were used for the measurement of endothelium-
dependent and endothelium-independent vasodilation respectively. Each dose of vasodilator 
was infused into the brachial artery for 5 minutes.
One week after completion of the experiment subjects received a questionnaire to evaluate late 
side effects.
Study 1: The acute vasomotor response to BVZ
Seven volunteers were recruited for this study. Forearm blood flow (FBF) was measured using 
venous occlusion strain gauge plethysmography. First, baseline FBF was recorded for 5 minutes. 
Subsequently, the vasomotor effect of BVZ was studied during a 15 minute infusion of BVZ (144 
µg/dl forearm volume/min) in the brachial artery of the non-dominant arm. Thirty minutes after the 
BVZ infusion FBF was assessed again for studying late effects of BVZ infusion. During the last 
minute of 15 minutes of BVZ infusion venous blood was collected from both arms to measure 
local and systemic concentrations of BVZ. 
BVZ concentration was measured with a 1-site enzyme-linked immunosorbent assay (ELISA 
developed by our laboratory. In short, 96-well plates (#655092, Greiner Bio-One, Alphen a/d Rijn, 
The Netherlands) were coated overnight at 4 °C with 100 µl VEGF (0.50 µg/ml, Genentech Inc, 
San Francisco, CA), washed (96PW plate washer, TecanGroup Ltd., Männedorf, Switzerland), 
and then blocked with 150 µl Superblock (#37515, Pierce, Rockford, IL) during 30 minutes at 
ambient temperature, washed and further blocked with 300 µl BSA (#A-7906, Sigma Chemical, 
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St. Louis, MO) for 4 hours at ambient temperature. Subsequently, the plate was washed 
and standards (range 0-10 ng/ml Avastin, Roche, Basel, Switzerland), study samples and a 
reference sample were pipetted into the wells and the plate was incubated overnight at 4 °C. 
After washing, the plate was incubated with 100 µl Mouse anti-Human IgG (Fc) POD, (dilution 
1:25,000, SouthernBiotech, Birmingham, U.K.) during 2 hr at ambient temperature and again 
washed. Thereafter incubation with 100 µl ready-to-use 3,3´, 5, 5´- tetramethyl-benzidine  (TMB) 
(solution (Kem-En-Tec, Taastrup, Denmark) for 15-20 minutes took place for colour development. 
The reaction was stopped by addition of 0.5 M H2SO4 and optical density was measured at 
450 nm in a Multiskan Ascent plate reader (Lab Systems, Oy, Helsinki, Finland). The analytical 
sensitivity, defi ned as the minimum BVZ concentration evoking a response signifi cantly different 
from that of the zero calibrator, was 16 pg/ml. Plasma samples, diluted 4,000 – 24,000 fold, 
exhibited excellent parallelism. To six plasma samples known quantities of Avastin were added. 
The recoveries ranged in the plasma samples from 87% to 110% with a mean recovery of 98%. 
In each run the reference preparation, prepared from a pool of plasma from patients treated with 
BVZ, was used to monitor long-term performance of the assay. The concentration in reference 
preparation was 1670 ng/ml, the within-run coeffi cient of variation (CV) and the between-run CV 
amounted to 7.0% and 10.0%, respectively.
Study 2: The effect of BVZ on endothelium dependent vasodilation
In twelve evaluable volunteers the vasodilator response to ACH was studied in absence and 
presence of BVZ. The experiment started with measurement of baseline FBF  during saline 
infusion during 5 minutes followed by two increasing dosages of ACH (0.5  and 2.0 µg/dl forearm 
volume/ min) 5 minutes each. After a washout period of 45 minutes measurements of FBF 
response to saline and the two increasing dosages of ACH were repeated during continuous 
infusion of BVZ during 15 minutes. 
Subjects with less than  a 100% increase in FBF in the absence of BVZ  were excluded, because 
of non evaluable baseline response to ACH and replaced by newly recruited volunteers.  
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Study 3: The effect of BVZ on endothelium independent vasodilation
In a separate group of twelve evaluable volunteers the vasodilator response to SNP in absence 
and presence of BVZ was studied. First baseline FBF was measured during glucose  infusion 
followed by two increasing dosages of SNP (0.06  and 0.2 µg/dl forearm volume/ min). After a 
washout period of 45 minutes measurements of FBF response to glucose and the two increasing 
dosages of SNP were repeated during continuous infusion of BVZ during 15 minutes.
Statistical Analysis
Statistical analysis was performed using the SPSS  (version 16.0) software packages. Values are 
reported as mean±SE unless otherwise specified. Mean arterial pressure (MAP) was measured 
continuously during each recording of FBF and averaged per FBF registration. Drug-induced 
effects were expressed as percentage of change from preceding saline or glucose infusion. The 
percentage changes in FBF to each dosage of a vasodilator substance were averaged to one 
value for each vasodilator. These values were compared using  a repeated measures ANOVA to 
assess the effect of BVZ.  Before analysis, logarithmic transformation was performed to obtain 
a Gaussian distribution. 
 
Results
In total 46 subjects signed informed consent. Five subjects were excluded based on medical 
history or medication use. Another 5 subjects withdrew consent for personal reasons prior to 
start of the study. 
Five subjects were excluded after completion of the study protocol due to an absent response 
to ACH as was prespecified in our study protocol.  In this study we choose healthy volunteers 
to rule out other factors influencing endothelial function such as medication, cardiovascular 
risk factors or underlying disease to assess the specific effect of BVZ on normal endothelial 
function.  Subjects with an absent response to ACH measurement, may have other unknown 
factors that already altered endothelial function and interfere with the response to BVZ. The 
percentage change in FBF in these five individuals compared to the mean FBF in the included 
group before and during BVZ are depicted in figure 1. As shown in this figure, the lack of 
response to ACH was reproduced in the presence of BVZ. excluding regression to the mean 
as a potential confounder that could have been introduced by this exclusion.  Thirty-one male 
subjects (23.9±1.2 years) were included in the analysis. 
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FIGURE 1
Percentage change in forearm blood fl ow (FBF; mL/dL forearm volume per minute) from baseline in response to 
acetylcholine represented as mean for the included group (n=12) and individual fl ows for the excluded individuals 
(n=5). BVZ indicates bevacizumab.
Study 1: The acute vasomotor response to BVZ
BVZ concentrations
At the end of the  15 minutes infusion of BVZ, BVZ reached a concentration of 136±13.2 µg/
ml (n=7) in the experimental arm, resembling plasma concentration after systemic exposure to 
BVZ in patients treated with 5mg BVZ i.v./kg. BVZ concentration in the control arm was 8.3 ±0.8 
µg/ml (n=7).
Intra-arterial BVZ did not  alter baseline forearm blood fl ow (Figure 2). Blood pressure did not 
change either (baseline MAP:77.1±2.7mmHg; at the end of BVZ infusion:79.5±2.2mmHg). 
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FIGURE 2
Percentage change from baseline in forearm blood fl ow (FBF) in response to bevacizumab (BVZ) infusion in the 
experimental forearm and control forearm. No acute vasomotor response to infusion of BVZ was observed.
Study 2: The effect of BVZ on endothelium dependent vasodilation
In the experimental arm, forearm blood fl ow increased from 1.3±0.2 at baseline to 5.5±1.1 and 
10.6±1.8 ml/dl/min  for the two increasing dosages of ACH (0.5 and 2.0 µg ACH/dl forearm/
min) respectively. In the presence of BVZ, ACH increased forearm blood fl ow from 1.4±0.2 to 
3.8±0.8 and 8.9±1.8 ml/dl/min respectively (fi gure 3). In the contralateral arm, forearm blood 
fl ow remained constant: 1.2±0.2, 1.1±0.2 and 1.2±0.2 ml/dl/min in the absence of BVZ and 
1.1±0.3, 1.0±0.2 and 1.2±0.2 ml/dl/min in the presence of BVZ for baseline and two subsequent 
ACH doses respectively (fi gure 3). In the absence of BVZ, ACH increased FBF from baseline 
by  440±157% and  926±252%). In the presence of BVZ, ACH increased FBF from baseline 
by  169±40% and  612±154% respectively (n=12; p< 0.05 for the effect of BVZ, ANOVA for 
repeated measures on log-transformed data; fi gure 4) . 
In the absence of BVZ, the percentage increase in forearm blood fl ow during sodium-nitroprusside 
(SNP) infusion was 270±45% (0.06  µg/dl/ min) and 671±162%  (0.2 µg/dl/ min). In contrast to 
ACH, the vasodilator effect of SNP was not affected by simultaneous infusion of BVZ  248±64% 
and 679±156% (n=12; p>0,4; fi gure 4) . For the course in forearm blood fl ow, see fi gure 3. 
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FIGURE 3
Study protocol and actual forearm blood fl ow (FBF) in response to 2 increasing dosages of acetylcholine (ACH) and 
sodium nitroprusside (SNP). BVZ indicates bevacizumab.
FIGURE 4
Increases in forearm blood fl ow (FBF) in response to 2 increasing dosages of acetylcholine and sodium nitroprusside, 
depicted as percentage change, from baseline. Error bars, SE of the mean. Statistical analysis was performed on the 
log-transformed data. BVZ indicates bevacizumab.
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Blood pressure and heart rate did not change in response to the vasodilator agents (see table 1). 
TABLE 1
 Blood Pressure and Heart Rate
ACH SNP
Infusion Period MAP, mm Hg Heart Rate, bpm MAP, mm Hg Heart Rate, 
bpm
Baseline 79.5 ±2.1 60 ±2 77.0 ±2.2 61 ±3
Vasodolator (low) 79.4 ±2.0 60 ±2 76.6 ±2.2 61 ±3
Vasodilator (high) 79.3 ±2.2 62 ±3 76.4 ±2.3 61 ±2
BVZ baseline 81.1 ±1.9 60 ±2 81.8 ±2.2 60 ±3
BVZ vasodilator (low) 81.0 ±1.9 62 ±3 81.0 ±2.1 60 ±3
BVZ vasodilator (high) 81.0 ±2.1 62 ±3 81.2 ±2.2 61 ±3
ACH indicates acetylcholine; BVZ, bevacizumab; MAP, mean arterial pressure; and SNP, sodum nitroprusside.
Side effects
No side effects of BVZ were reported during infusion or at 1-2 weeks after the experiment as 
evaluated by a questionnaire. 
Discussion
In the present study, we show for the fi rst time in humans that inactivation of circulating  VEGF 
decreases endothelium dependent vasodilation within 15 minutes. This proves that circulating 
VEGF plays a role in maintaining normal endothelial control of vascular tone. 
Previously, several clinical studies have shown decreases in endothelium dependent but also 
endothelium independent vasodilation during treatment with tyrosine kinase inhibitors targeting 
VEGF signaling10, 11. However these studies have been conducted after at least six weeks of 
anti-VEGF treatment when rise in blood pressure already had occurred. Hypertension by itself 
decreases endothelial function. Prolonged treatment with TKIs targeting the VEGF pathway has 
been reported to be associated with capillary rarefaction11, 12. Rarefaction increases vascular tone 
and interacts with both endothelium dependent and independent vasodilation. Rarefaction also 
occurs in  idiopathic (essential) hypertensive patients13, 14 and could therefore be a consequence 
rather than a cause of the rise in blood pressure that often occurs during treatment with these 
drugs. A recent study in swine showed an increase in blood pressure within a few hours after 
administration of sunitinib, a TKI targeting the VEGF pathway 15. The fast onset of changes in 
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blood pressure makes rarefaction a less likely cause of VEGF targeting TKI-induced hypertension 
and suggests that  rarefaction is a consequence rather than a cause of hypertension in this 
group of patients.
In this study, intra-arterial infusion of BVZ achieved a clinically relevant concentration of BVZ in 
the forearm while systemic exposure to this drug was low. This allowed us to study the local 
effect of selective VEGF deprivation without interference of systemic effects such as a rise in 
blood pressure. Bevacizumab  selectively interrupts endogenous VEGF signaling. This contrasts 
with tyrosine kinase inhibitors such as sunitinib, which to do not only inhibit VEGF signaling 
but also the response to other growth factors such as PDGF or c-Kit. 11. Finally, we studied 
healthy volunteers,  without any co-medication that could interfere with vasomotor control  such 
as chemotherapy 10. Therefore, a strength and unique feature of our study is the specificity of the 
used pharmacological intervention. 
We did not observe an effect of  BVZ on vascular tone. This  suggests that the effect on the 
muscle vascular bed is not sufficient to cause hypertension. However some remarks can be 
made about this conclusion. BVZ was infused for 15 minutes. The infusion time was based 
on previous investigations that showed a decrease in blood pressure in response to VEGF-
infusion within a few minutes16. More importantly, time was limited by the allowed exposure of 
healthy volunteers to this drug. The given dose was high enough to reach local concentrations 
mimicking concentrations after systemic exposure in patients, but the  continuous arterial influx 
of free non-bound VEGF could have resulted in some residual VEGF receptor stimulation in our 
experimental set-up and could therefore have underestimated the effect as observed during 
systemic therapy with BVZ. In addition, regional differences in the role of VEGF on baseline 
vascular tone may exist.
Several previous studies ( Kappers et al) have shown that activation of the endothelin axis may be 
involved in the onset of hypertension during inhibition of VEGF signaling. The reported decrease 
in endothelium dependent vasodilation in our study could be due to diminished release of nitric 
oxide, as supported by the previously mentioned studies6-9 . It has been previously shown that 
the inhibition of baseline NO can enhance the release of endothelin-117 18.  Thus, our observation 
provides a clue to a potential mechanism of increased endothelin-1 release in response to 
VEGF-targeted therapy. 
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Perspectives
 
Our observation does not exclude the possibility that BVZ increases vascular tone in other organs 
such as the kidney which is of particular interest with regard to the pathogenesis of hypertension. 
Our results indicate that local VEGF deprivation immediately reduces endothelium-dependent 
vasodilation, however, this study does not allow any conclusion on the mechanism of this 
altered endothelial function. Apart from a reduced release of NO, reduced formation of other 
endothelium-derived relaxing factors or an increased release of endothelium-derived contracting 
factors in response to acetylcholine may have contributed to  this observation.  
Conclusion
 
Our study is the first to investigate the acute effect of VEGF inhibition on vascular tone and 
endothelial function in healthy volunteers. It was performed in healthy volunteers to prevent 
a possible influence of previous and current medical treatment or disease on the vascular 
response to VEGF inhibition.  Our study using a specific VEGF antibody suggests a role for 
circulating VEGF in normal endothelial control of vascular tone.
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Abstract
 
Tyrosine kinase inhibitors targeting angiogenesis have become an important part of the treatment 
of patients with several types of cancer. One of the most reported side effects of VEGFR targeted 
therapies is hypertension. In this study we hypothesized that the development of hypertension 
in patients treated with sunitinib, a multitargeted tyrosine kinase inhibitor, is preceded by 
reduced endothelium dependent vasodilation. Moreover we hypothesized that this endothelial 
dysfunction is a result of impaired nitric oxide release.In a placebo-controlled experiment we 
determined vascular responses in isolated mesenteric arteries of  rats (n=26) after 7 days of 
sunitinib treatment. Sunitinib reduced endothelium dependent vasodilation, but not endothelium 
independent vasodilation. Moreover we observed that the difference in endothelium dependent 
vasodilation between controls and sunitinib-treated animals disappeared in the presence of 
L-NAME, a nitric oxide-antagonist. In patients with metastatic renal cell carcinoma, before and 
one week after start of sunitinib, the endothelium-dependent vasodilator response to intra-
arterial acetycholine and the endothelium-independent vasodilator response to intra-arterial 
sodium nitroprusside was assessed with venous occlusion plethysmography. No changes in 
forearm bloodflow ratios were observed.. Mean arterial pressure did significantly increase from 
101.9 ±3.8 mmHg to 106.1 ±2.6 mmHg after one week and further to 115.8 (±4.9) mmHg after 
two weeks of treatment. 
Conclusion 
In animals, this study confirms that exposure to high concentrations of sunitinib reduces 
endothelium-dependent vasodilation by reducing endothelial release of nitric oxide. In humans 
however, reduced endothelium-dependent vasodilation does not precede the development of 
hypertension in patients treated with sunitinib.  
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Introduction
 
Tyrosine kinase inhibitors (TKIs) targeting angiogenesis have become an important part of the 
treatment of patients with several types of cancer1,2. From the hypothesis of Folkman in 19713 
about the need of angiogenesis for tumor growth to the introduction of the newest angiogenesis 
inhibitors more than 40 years have passed in which a lot of the therapeutic opportunities of 
targeting angiogenesis have become clear, but also showing several side effects of these 
treatments.
Sunitinib is an oral TKI, targeting VEGFR1-3, PDGFRA and PDGFRB, c-KIT , FLT3,  CSF-1R, 
and RET. It is used widely as it has been approved for the treatment of metastatic renal cell 
carcinoma, gastrointestinal stromal tumor (GIST) and neuro-endocrine tumors of the pancreas.  
One of the most reported side effects is hypertension. Hypertension occurs in 19% to 80% of 
patients4-6. Even more patients experience a rise in blood pressure7. Hypertension is correlated 
with improved progression free survival in patients with metastatic renal cell carcinoma treated 
with sunitinib and with bevacizumab, a monoclonal antibody against vascular endothelial growth 
factor (VEGF) 6,8. 
The common pathway in the development of hypertension in the course of treatment with this 
class of drugs is VEGF.  VEGF is an angiogenic growth factor, which is mainly secreted from 
mesenchymal, stromal and epithelial sources to act on endothelial cells. The angiogenic effects 
of VEGF are primarily mediated by VEGF receptor-2 (VEGFR-2).  VEGF plays an important role 
in the proliferation of new  blood vessels necessary for tumor growth9,10. VEGF and its receptors 
are also expressed in many normal tissues. Different studies show that exogenous VEGF causes 
hypotension11. In animal experiments, VEGF  induces hypotension due to synthesis and/or 
release of nitric oxide (NO)12. In human  umbilical vein endothelial cells treatment with VEGF 
resulted in both an acute (1 h) and chronic (>24 h) stimulation of NO production13. In mice, 
inhibition of VEGF receptor-2 rapidly increased blood pressure and reduced the expression of 
NO synthases in the kidney. Moreover, treatment with a NO-synthase antagonist abolished the 
effect of VEGF receptor-2 inhibition on blood pressure14. On the basis of this knowledge inhibition 
of VEGF in humans could result in a decrease in NO availability which could subsequently trigger 
the development of hypertension. In a previous study we have shown that selective scavenge of 
endogenous VEGF by intra-arterial infusion of bevacizumab decreases endothelium-dependent 
vasodilation acutely15. This supports the hypothesis that VEGF inhibition causes endothelial 
dysfunction and may cause hypertension by increasing vascular resistance in humans.   
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Besides the possible effects of VEGF inhibition on endothelial function some studies show that 
neurohormonal changes can play a role in the development of hypertension during treatment 
with angiogenesis inhibitors. For example in patients with mRCC and gastrointestinal stromal 
tumors administration of sunitinib was associated with a rise of plasma endothelin-1 (ET-1) 
concentration16. And other studies show that vascular rarefaction can occur during treatment 
with a small molecule angiogensis inhibitor17. In this study however we will focus on changes in 
endothelial function. 
Previous studies in humans treated with VEGF-targeted therapies have shown a decrease in 
endothelial function after 6-10 weeks of treatment, however at that time point hypertension 
already occurred, so whether endothelial dysfunction precedes hypertension and is a cause 
rather than a consequence of  the rise in blood pressure is unknown17 Preclinical studies show 
that the occurrence of hypertension is accompanied by a decrease in urinary excretion of NO 
metabolites and reduced endothelium-dependent vasodilation in the coronary vasculature 16. 
However, the exact role of NO in this sunitinib-induced endothelial dysfunction has not been 
studied before. 
Therefore, we performed a preclinical and a clinical experiment. In sunitinib-treated animals and 
appropriate controls, endothelium-mediated vasodilation was assessed, as well as  the role 
of NO in this vascular response. In a clinical study in mRCC patients who started  treatment 
with sunitinib, we investigated whether the effect on endothelium-mediated vasodilation, as 
previously described, occurs before the onset of hypertension.
 
Material and Methods 
Animals
The experimental protocol was approved by the Animal Experiments Committee of the Radboud 
university medical center and was performed according to the European guidelines on animal 
experiments.  Male Wistar-Hannover rats ( Harlan) were used in the experiments (n=28, 180-
200g). Rats were housed in pairs in filter-top cages on a 12-h light/dark cycle, having access to 
standard laboratory rat chow and water ad libitum. Rats were randomly assigned to treatment 
for 7 days with either sunitinib 25 mg/kg or vehicle administrated by oral gavage. The content 
of sunitinib capsules, obtained from patients who discontinued therapy, was dissolved in 
hydrochloride (0.1 mmol/l) containing 0.5% polysorbate 80 and 10% polyethylene glycol 300 
adjusted to pH 3.5-3.7 to a concentration of 12.5 mg/ml. On day 8 the rats were euthanized. 
Subsequently, the intestine and mesenteric vessels were removed and immediately immersed in 
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physiological salt solution (PSS, constituents in m M: NaCl 119, KCl 4.7, CaCl2 2.5, NaHCO3 25, 
MgSO4 1.2, KH2PO4 1.2, EDTA 0.027, and glucose 5.5). Four to eight second order mesenteric 
resistance arteries (diameter 150–400 µm) per rat were dissected and mounted in a Mulvany wire 
myograph in PSS (Dual Wire Myograph model 400A; J.P. trading and the DMT multi-chamber 
wire myograph)  and oxygenated with 95% O2 and 5% CO2 at a temperature of 37
oC. From the 
diameter-tension relation of the unstimulated vessels, the internal diameter was calculated and 
the vessels were set on the normalized diameter corresponding to 90% of the diameter at a 
transmural pressure of 100 mm Hg.  Investigators were blinded for therapy allocation.
In at least two arteries of each rat the endothelium dependent vasorelaxation was determined 
after precontracting the arteries with U46619 (thromboxane A2 analog, Sigma-Aldrich, the 
Netherlands); after 25 minutes, a cumulative dose-response curve to acetylcholine (ACh, Sigma-
Aldrich, the Netherlands) was obtained. In a subgroup of 14 rats,  in at least  two arteries from 
each rat, the endothelium independent vasorelaxation was determined by constructing a dose-
response curve to the NO-donor sodium-nitroprusside (SNP, Riedel-de Haen, the Netherlands) 
after precontraction with U46619.
To determine the role of NO in the sunitinib-induced changes in  endothelium dependent 
vasorelaxation,  the ACh-induced relaxation was determined in a subgroup of 14 rats, in at least 
two arteries per rat, in the presence of the NO-synthase-antagonist L-NAME ( 10-4M)(Sigma-
Aldrich, the Netherlands).
Humans
After approval of the protocol (NCT01227213) by the Institutional Review Board of the Radboud 
university medical center a total of 10 patients with metastatic renal cell carcinoma (mRCC) 
starting treatment with sunitinib were recruited after written informed consent. Patients were 
eligible if they had a life expectancy  of more than 12 weeks, a WHO performance status of 0-2 
and no evidence of severe or uncontrolled diseases other than renal cell carcinoma. Patients 
treated with corticosteroids or oral anti-coagulants were excluded.  A history of hypertension 
was not an exclusion criterium, but had to be controlled ( <150/100 mmHg, the threshold 
for grade I toxicity according to the common terminology criteria of adverse events (CTCAE) 
version 3) before start of sunitinib.  All studies were performed according to institutional and 
Good Clinical Practice guidelines. In the week before and one week after starting treatment with 
sunitinib (50 mg/day) the forearm blood flow (FBF) response to the endothelium-dependent 
vasodilator acetylcholine (ACh) and the NO-donor nitroprusside (SNP) was measured using 
venous occlusion plethysmography. Venous occlusion plethysmography is an well established 
method to measure changes in microcirculation and endothelial function18,19
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The experiments were performed after at least 24 hours of caffeine abstinence, in the morning 
after an overnight fast and caffeine abstinence. Subjects were allowed to take their medication 
(including sunitinib) in the morning of the experiment with a cup of water.  Subjects were studied 
in supine position in a temperature-controlled room (23±1ºC). At the start of each experiment 
a 27-gauge needle (Braun Medical BV, Oss, the Netherlands) was inserted into the brachial 
artery of the non-dominant arm for intra-arterial administration of saline, ACh ( Miochol, Thea 
Pharma NV, Zoetermeer, the Netherlands)  and SNP ( 50 mg dry powder, Spruyt Hillen, the 
Netherlands; dissolved to its final concentration with 5% glucose solution; Clinical Pharmacy, 
Radboud university  medical center).
During intra-arterial infusion of solvent (NaCl 0.9% for ACh and glucose 5% for SNP) or vasodilators, 
forearm blood flow (FBF) was measured at both arms simultaneously, using electrocardiogram-
triggered venous occlusion mercury-in-silastic strain-gauge plethymography (Hokanson EC4, 
Hokanson, Inc). During all FBF  recordings  the hand circulation was completely occluded using 
wrist cuffs inflated to 200 mmHg.  At least 30 minutes after the cannulation experiments were 
started. Drugs or solvent  were infused at a constant rate of 50 µl/dl forearm/ min. 
The experiment started with the measurement of baseline FBF during saline infusion during 5 
minutes followed by 3 increasing dosages of ACh (0.5, 2.0 and 8.0 µg/dL  forearm volume per 
minute) 5 minutes each. After a washout period of 30 minutes, FBF responses to glucose and 
3 increasing dosages of SNP (0.06,0.2 and 0.6 µg/dL ) were measured. Fifteen minutes after 
removal of the needle blood pressure was measured in the opposite arm in supine position 
using an automated blood pressure device (Welch Allyn Vital Signs 5300P).
Sunitinib measurement
Sunitinib concentrations were measured in the sunitinib-treated rats. In patients ,after analysis of 
the primary endpoints, sunitinib was measured in the plasma  samples that were available after 
one week of treatment (n=6).  Plasma samples were prepared according to the methodology 
adapted from Rodamer et al20. Plasma samples were deproteinized by addition of acetonitril 
containing Sunitinib-D10 ( Toronto Research Chemicals inc,)  as internal standard. Ten microliter 
of the supernatant is injected onto the LC-MS/MS system. Separation was performed with a 
Grace, VisionHT C18 column (1,5µm 50x2,0mm). The mobile phase, consisted of 66.6% 
acetonitril, 25% 20mM NH4Ac pH 7.8, 8.3% methanol. For the mass spectrometric analysis, 
heated electrospray ionization (HESI) was operated at a spray voltage of +3kV, the capillary 
temperature and the vaporizer temperature were set at 250 and 325°C respectively. Argon was 
used as collision gas at a pressure of 1.5 mTorr. Positive ion mode was used with selected 
reaction monitoring (SRM) for the quantitation. The following SRM transitions were used: m/z 
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399.1(parent ion) to m/z 283.1 and 326.1 (both product ions) for sunitinib and m/z 409.4(parent 
ion) to m/z 283.2 and 326.2 (both product ions) for sunitinib-D10.
 
Statistical Analysis
Animals
Vascular contraction was determined as a percentage of precontraction (100%). The data are 
expressed as mean ± standard error of the mean; n indicates the number of animals. Values of 
the different arteries per rat were averaged. If less than two arteries of a rat in a single experiment 
met the predetermined quality criteria (precontraction  to U46619 at least 8 mN) this rat was 
excluded from the analysis. Emax was defined as the contractile force at maximum relaxation 
to the vasodilator expressed as percentage of baseline. Comparisons between sunitinib treated 
and vehicle treated rats were made using the Mann-Whitney U test. P values < 0.05 were 
considered to be significant. Adequate curve fitting could not be achieved due to the attenuated 
relaxation in the sunitinib treated rats. 
Humans 
Data were analyzed using the SPSS (version 16.0) software packages. Values are reported as 
mean±SE unless otherwise specified.
Drug-induced effects were expressed as percentage change in FBF-ratio (infused arm/control 
arm) from preceding saline or glucose infusion. To this end, FBF ratios were calculated for each 
set of simultaneously measured FBFs separately. FBF-ratio’s were averaged to one value for 
baseline (last 2 minutes) and for each vasodilator dose (last two minutes of each dose). For 
each dose the percentage change in FBF-ratio from baseline were calculated.  After logarithmic 
transformation to obtain a Gaussian distribution, the effect of sunitinib was analysed using a 
repeated measures ANOVA (vasodilator dose and sunitinib therapy as within-subject factors). 
The effect of sunitinib on blood pressure was analysed using a paired student-T-test. Two-sided 
p-values < 0.05 were considered to indicate statistical significance.
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Results
Animals
Body weights of vehicle and sunitinib treated rats were 265 ± 6 g (n=13) and 249 ± 8 g (n=13) 
(p<0.05) respectively. The diameter of the mesenteric resistance arteries used in this study was 
272.6 ± 6.6  µm for vehicle rats (n= 55 vessels) and 250.1 ± 6.3  µm for sunitinib rats (n= 63 
vessels) (p<0.05). Two rats, one in each group, died before day 7 for reasons not related to the 
treatment and were therefore  excluded from the study protocol.  
ACh-induced vasorelaxation
In 24 rats (12 on sunitinib) ACh induced vasorelaxation was analyzed. Maximum ACh-remaining 
vasoconstriction (Emax) in arteries precontracted with U46619 was significantly lower in control 
rats ( 11.1 ± 2% compared to sunitinib rats (35.4 ± 8.9%)(p<0.05), see figure 1A.
ACh-induced vasorelaxation in the presence of L-NAME
In a subgroup of 14 rats (7 on sunitinib) ACh relaxation was measured in the presence of the NO 
synthase antagonist  L-NAME (10-4 M). In the control group L-NAME significantly attenuated the 
maximum response (Emax) to ACh (46.1 ± 14.2%) compared to ACh alone (9.5 ±3.6%) (p<0.05) 
in the same rats; figure 1C. In the sunitinib group L-NAME did not decrease the response to 
ACh ( 43.1 ± 14.6%) compared to ACh alone (46.4 ± 13.7) in the same rats (n=7); figure 1D. 
Emax values in response to ACH in presence of L-NAME were not significantly different between 
sunitinib and control groups. Thus, L-NAME significantly reduced the vasodilator response to 
ACh in the controls alone and not in the sunitinib treated rats. The difference in ACh-response 
between controls and sunitinib-treated animals disappeared after incubation of the vessels with 
L-NAME.
SNP-induced vasorelaxation
In a subgroup of 10 rats (6 on sunitinib) SNP induced vasorelaxation was measured. No 
differences were observed between groups; figure 1E.   
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FIGURE 1
Vascular responses in animal study. (a) Endothelium-dependent relaxation (ACH). (b) Endothelium-dependent 
relaxation (ACH) in presence of L-NAME. (c) Endothelium-dependent relaxation (ACH) with and without 
L-NAME in control rats. (d) Endothelium-dependent relaxation (ACH) with and without L-NAME treated rats. 
(e) endothelium-independent relaxation with SNP
4
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Humans
10 patients signed informed consent and were included in the study. All subjects were male 
with a median age of 60 years ( range 27-68 years); table 1. Six patients were already on 
antihypertensive medication before the inclusion in the study.  The type of antihypertensive 
medication is shown in table 1. All patients had mRCC and sunitinib was the choice of treatment 
as decided by their oncologist. 
TABLE 1 
 Baseline characteristics (mean ± SD)
Patient characteristics Baseline 1 week 2 weeks
N 10 10 10
Age (mean ± SE) 55 ±12
BMI (mean ± SE) 28.7 ± 5.7
Hypertensive medication (n) 6 6 6
Calcium antagonist 4 4 4
Beta-Blocker 2 2 2
RAAS inhibitor 3 3 3
Thiazide diuretics 2 2 2
Blood Pressure > 140/90 mmHg 3 4 8
MAP (mmHg) 101.9 ± 12 106.2 ± 8.3 115.8 ±15.8
Systolic pressure (mmHg) 138.4 ± 14.6 140.3 ± 11.1 151.2 ± 20.8
Diastolic pressure (mmHg) 83.8 ± 12.7 89.1 ± 9.1 98.2 ± 14.7
Heart rate (bpm) (n=9) 67.6 ± 8.3 65.7 ± 9.4 NA
Baseline FBF (ml/dl) 1.6 ± 0.8 1.7 ±1.2 NA
FBF, forearm blod flow; MAP, mean arterial pressure; RAAS, renin-angiotensin-aldostreine system
ACh-induced vasorelaxation
Before the start of sunitinib FBF increased in the infused forearm from 1.6±0.3 mL/dL at baseline 
to 3.5±0.6 mL/dL, 7.1±1,6 mL/dL and 8.9±1,4 mL/dL per minute for the 3 increasing dosages of 
ACh (0.5 and 2.0 and 8.0 µg ACh/dL forearm per minute), respectively. After one week treatment 
with sunitinib, ACh increased FBF from 1.7±0.4 ml/dl to 3.9±0.6, 5.4±0.8  and 8.2±1.1 mL/dL 
per minute, respectively (figure 2).  In the absence of sunitinib, ACh increased median FBF-ratio 
(interquartile ranges) from baseline by 181 (49-321) %, 252 (103-885)% and 586 (191-1608)%. 
In the presence of sunitinib, ACh increased FBF ratio from baseline by 76 (25-388)%, 341 (25-
454)% and 338 (24-1004)% respectively (n=10; P>0. 1  for the effect of sunitinib,; figure 3). 
There is one outlier in the graph showing very high responses to both vasoactive substances 
(ACH and SNP) before the start of sunitinib. Exclusion of this outlier however does not change 
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the conclusion or interpretation of the experiments. For transparency we therefore included this 
patient in the analysis and graphs. 
FIGURE 2
 Study protocol and actual forearm blood fl ow in response to 3 increasing dosages of acetylcholine and sodium 
nitroprusside baseline and after 1 week of sunitinib treatment
SNP-induced vasorelaxation
Before the start of sunitinib FBF increased from 1.3 ±0.2 mL/dL at baseline to 4.0±0.4 mL/
dL, 6.9±0.7 mL/dL and 11.0 ±1.2mL/dL  per minute after three  increasing dosages of SNP 
(0.6 and 2.0 and 6.0 µg SNP/dL forearm per minute), respectively. After one week of treatment 
with sunitinib, SNP increased FBF from 1.5±0.3mL/dL  to 3.6±0.5mL/dL, 6.0±0.7mL/dL and 
8.9±1.1mL/dL  per minute, respectively (fi gure 3).  In the absence of sunitinib, SNP increased 
median FBF ratio (interquartile ranges) from baseline by 183 (86-1288)%, 474(167-2039)% and 
886 (357-4439)%, respectively. After one week of sunitinib, SNP increased median FBF ratio 
(interquartile ranges) from baseline by 202(128-399)%, 325(220-1171)% and 1050(269-2889)% 
(n=9; P>0.1  for the effect of sunitinib; fi gure 4). In one patient it was not possible to perform the 
experiment with SNP due to repetitive dislocation of the needle. 
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FIGURE 3 
 Individual increases in forearm blood flow ratio (FBF-ratio) in response to 3 increasing dosages of ACh, depicted as 
percentage change from baseline. Below the horizontal axis in boxes the median FBF ratio and interquartile ranges.  
Statistical analysis was performed on the log-transformed data.  = patient 2
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FIGURE 4 
 Individual increases in forearm blood flow ratio (FBF-rato) in response to 3 increasing dosages of SNP, depicted as 
percentage change from baseline. Below the horizontal axis in boxes the median FBF ratio and interquartile ranges. 
Statistical analysis was performed on the log-transformed data.  = patient 2
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Blood pressure
In the 10 patients mean arterial  pressure (MAP) before the start of sunitinib was 101.9±3.8 
mmHg (mean ± SE). After one week of treatment with sunitinib the  MAP increased to  106.2±2.6 
mmHg (p>0.1,not significant). After two weeks of sunitinib treatment MAP was 115.9±4.9 
mmHg  a significant increase compared to baseline  MAP (p=0.02) and compared to one week 
after start of sunitinib (p=0.03). MAP increased from baseline by more than 5 mmHg in two 
patients at week 1 and seven patients at week 2. After 2 weeks of treatment in total eight patients 
met the criteria of hypertension (> 140/90mmHg, International Society of Hypertension (ISH)), 
while all used the same antihypertensive medication as on baseline. At the visit at week 2, after 
recording of blood pressure, antihypertensive medication was changed or started by the treating 
oncologist to control hypertension.
Sunitinib concentrations
Total plasma sunitinib concentration in rats (n=8) was 134.4 ± 8.6 ng/ml after one week of 
treatment. In patients (n=6) after one week of treatment the mean concentration was 43.1 ± 
8.1 ng/ml. 
Discussion
Hypertension is an important side effect of VEGFR targeted therapies. In our studies we 
aimed to obtain insight in the early factors  preceding and contributing to the development 
of hypertension. In the present study we focused on the effect of sunitinib on ACh-induced 
endothelium-dependent vasodilation as a reflection of endothelial function.
We show that in a sample of 10 patients who started sunitinib and in whom blood pressure increased 
in almost all at the end of 2 weeks of therapy, ACh induced endothelium-mediated vasodilation 
is not attenuated prior to the observed increase in blood pressure. Therefore impairment in 
endothelium-dependent vasodilation does not trigger sunitinib-induced hypertension. 
In contrast to the human study, in rats treated for 7 days with sunitinib we did see a decreased 
endothelium-dependent vasorelaxation without a change in  endothelium-independent 
vasorelaxation. Moreover in the rats we observed that the effect of sunitinib on ACh induced 
vasorelaxation was similar to the inihibitory effect of a NO-antagonist and that the difference 
in ACh-induced vasodilation between controls and sunitinib-treated animals disappeared in 
the presence of L-NAME. These observations are in agreement with previous studies showing 
the effect of VEGFR inhibition on NO synthase expression and NO-availability in pre-clinical 
studies14,21.  
4
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In comparison with patients the sunitinib concentrations in our rats were higher and well above 
human therapeutic concentrations. Moreover previous studies have shown that rats treated 
with sunitinib 25mg/kg already have an increase of 20 mmHg  in blood pressure after 2 days 
of treatment22. The observed endothelial dysfunction in rats could therefore be a consequence 
of hypertension rather than the preceding cause.  This is supported by a previous clinical study 
conducted in patients after at least 6 weeks of treatment with a VEGFR inhibitor, when rise in 
blood pressure already had occurred, which showed a decrease in endothelium-dependent 
vasodilation17. This study is difficult to interpret however, since also endothelium-independent 
vasodilation was reduced by sunitinib suggesting that endothelium-independent actions of the 
angiogenesis inhibitor such as structural vascular changes. This is supported by our finding 
that the vascular diameter of the arterioles was smaller in sunitinib treated rats. However in our 
preclinical study it did not hamper endothelium independent vasodilation.
In a previous experiment in healthy volunteers we observed that bevacizumab, a monoclonal 
antibody against VEGF, does acutely attenuate the vasodilator response to ACh15. Selective 
interruption of VEGF signaling presumably has a different effect on vascular function than the less 
selective inhibition of multi-targeted kinase inhibitors such as sunitinib. This observation implies 
that vascular and hemodynamic effects  induced by these TKIs are not solely dependent on 
interruption of VEGFR signaling but also on other  targeted pathways .  
Finally, some limitations of our studies should be mentioned. First, the number of included patients is 
rather limited and there is some variation in blood pressure and medication between patients before 
the start  of the study. And moreover only male patients were included in this study.  This is however  a 
reflection of the general mRCC population23  and given the invasive procedure in a fragile population 
we considered it not appropriate to extend the number of patients beyond the power calculation, which 
was based on previous studies in our center. Apart from the start of sunitinib no other medication 
was started or changed during the study period and blood pressure lowering medication at baseline 
did not prevent the occurrence of hypertension. In theory antihypertensive medication used by 
patients in our study could have reduced the impact of sunitinib on endothelial function, however 
blood pressure still increased in this patient group, not preceded by impaired endothelial function, 
indicating that the increase in blood pressure is not explained by an effect on endothelial function. 
Therefore co-medication did not hamper the interpretation of our study. We conducted this study to 
investigate early changes in endothelial function before the onset of hypertension. Our observations 
indicate that changes in endothelial function could play a role in sustaining or increasing the elevated 
blood pressure but not in the early development. Moreover, given the need to start active and 
standard treatment in patients with progressive metastatic disease, it was not deemed proportional 
to perform a placebo controlled study with the first aim of understanding the cause of hypertension 
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Perspectives
Future investigations should focus on other mechanisms than changes in endothelial function 
such as structural changes in the vascular bed or neurohormonal changes affecting the vascular 
system as a precursor of the development of hypertension. 
 
Conclusion
In animals, this study confirms that exposure to high concentrations of sunitinib reduces 
endothelium-dependent vasodilation. As a novel finding, this study demonstrates that this 
endothelial dysfunction results from reduced endothelial release of NO. In humans however, 
reduced endothelium-dependent vasodilation does not precede the development of hypertension 
in patients treated with sunitinib.  Therefore other factors should play a role as triggers for the 
development of hypertension. 4
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Abstract
Introduction
Although hypertension is one of the most frequently reported side effects in patients treated with 
the VEGFR tyrosine kinase inhibitor sunitinib, its mechanism is still not well understood. It is unclear 
whether previously reported hormonal changes are a result or a cause of the rise in blood pressure. 
Therefore, we studied early effects of sunitinib on renin, aldosterone and endothelin plasma levels. 
Methods
In 20 mRCC patients blood samples were obtained before and one week after the start of 
sunitinib 50mg per day, 4 weeks on-2 weeks off. Blood pressure (RR) was measured before, one 
and two weeks after the start of sunitinib.
Results
Eleven patients (55%) were on antihypertensive medication (AM) before the start of sunitinib. AM 
did not change in the first two weeks, except in one patient who needed an increase in dosage 
after 10 days. MAP increased from 100.1±2.4 at baseline to 104.6±2.0 at week 1 (not significant) 
and 110.1±3.4 mmHg at week 2 (p<0.05). Plasma endothelin increased from median 3.0 pg/
mL (2.3-3.9) to 4.5 pg/mL (3.4-6,4) (p<0.05) at week 1 and aldosterone levels increased from 
median 0.25 nmol/L (0.18-0.30) to 0.39 nmol/L (0.24-0.53) (p<0.05) at week 1. Plasma renin was 
not significantly affected. The rise in MAP after two weeks was significantly correlated with the 
rise in aldosterone (r2= 0.56; p=0.01) but not with endothelin (r2= 0.04  ; p=0.88 ) at week 1. 
Conclusion
Aldosterone/renin-ratio significantly increased after one week of sunitinib use, indicating an 
adrenal effect of sunitinib on aldosterone release. The rise in aldosterone is correlated with 
the increase in blood pressure after two weeks suggesting that aldosterone contributes to the 
early phase of hypertension in sunitinib-treated patients.  Therefore antihypertensive medication 
targeting the aldosterone receptor, such as spironolactone, could be an option to treat sunitinib- 
induced hypertension.
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Introduction
Tyrosine kinase inhibitors (TKIs) targeting the angiogenesis pathway have a key role in the 
treatment of several types of cancer(1, 2). Unfortunately these therapies are not without side 
effects. Sunitinib is an oral TKI, targeting VEGFR1-3, PDGFRA and PDGFRB, c-KIT , FLT3,  CSF-
1R, and RET. It is used widely as it has been approved for the treatment of metastatic renal cell 
carcinoma, gastrointestinal stromal tumor (GIST) and neuro-endocrine tumors of the pancreas.  
A frequently reported side effect of VEGFR-TKIs  is hypertension. Hypertension occurs in up to 
80% of patients treated with sunitinib depending on the used definition for hypertension (3-5). 
Even more patients experience a rise in blood pressure(6). In patients with metastatic renal 
cell carcinoma, the anti-tumor effect of  sunitinib, or other angiogenesis inhibitors, such as the 
monoclonal antibody against vascular endothelial growth factor (VEGF),  correlates with the 
development of hypertension (5, 7, 8). At the same time, this hypertensive effect limits the use of 
these effective drugs as it may contribute to heart failure or cardiovascular events, which occur 
in up to 33% of the patients treated with blockers of VEGF-signaling(9). Therefore, it is important 
to treat sunitinib-induced hypertension promptly and to prevent organ dysfunction associated 
with its use. 
The mechanism of VEGFR-TKI induced hypertension is not clear. Several studies regarding 
pre-eclampsia, a condition that is associated with the placental production of an endogenous 
scavenger of VEGF thus  mimicking pharmacological VEGF-inhibition, have shown the involvement 
of the renin-angiotensin system in development of hypertension in pregnancy(10, 11). On the 
other hand, recent observational data in patients with pre-eclampsia suggest involvement of 
endothelin-1 as well, paralleled with suppression of the renin-angiotensin system(12). In contrast 
to pre-eclampsia, however, there is currently no evidence for the involvement of the renin-
angiotensin-aldosterone system in the mechanism of sunitinib-induced hypertension. A previous 
study showed the activation of the endothelin system  without significant change in aldosterone 
as measured after 4 weeks of treatment with sunitinib (13). In rodents, endothelin receptor 
antagonists reduce the increase in blood pressure associated with sunitinib therapy (14). So, 
currently endothelin seems more important than aldosterone in sunitinib-induced hypertension, 
providing a strong case for endothelin receptor antagonists to be explored as a treatment for 
sunitinib-induced hypertension and organ damage in humans. However, endothelin receptor 
antagonists are expensive and pharmacokinetic interactions with sunitinib can occur as they 
can affect CYP3A4 metabolism(15). In humans, hormonal changes early in the treatment with 
sunitinib, before the full hypertensive response has developed, are not yet known. These early 
neurohumoral changes are important as they better reflect the direct actions of sunitinib as 
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opposed to secondary neurohumoral changes that could result from changes in blood pressure. 
Since angiotensin II may induce endothelin release(16)  we hypothesize that sunitinib activates 
the renin angiotensin system early after start of treatment and thereby serves as a trigger of 
hypertension and the increase in endothelin-1. We performed a clinical study in mRCC patients, 
who started treatment with sunitinib, to investigate the early changes in aldosteron, renine and 
endothelin and their correlation with the onset of hypertension. 
 
Methods 
After approval of the protocol  by the Institutional Review Board of the Radboudumc and 
prospective registration at www.clinicaltrials.gov (NCT01227213) 20 patients with metastatic 
renal cell carcinoma in which sunitinib was the treatment of choice signed informed consent for 
one of two sub-studies. In the first 10 patients, the impact of sunitinib on endothelial function 
of the forearm microcirculation was studied(17). In the subsequent 10 patients, the effect of 
sunitinib on insulin-sensitivity was explored(18). In all these patients, plasma was sampled to 
measure renin, aldosterone and endothelin.  
Patients using corticosteroids, oral anti-coagulants or any evidence of severe or uncontrolled 
diseases other than renal cell carcinoma were excluded. All patients had a WHO performance 
status 0-2 and a life expectancy of more than 12 weeks at time of inclusion.
Patients were followed during the first two weeks of treatment with sunitinib which was taken 
according to a 4 weeks ‘on’/ 2 weeks ‘off’ regimen with a starting dose of 50mg per day. In case 
of adverse events, according to the judgment of the patient’s oncologist, the dose could be 
decreased. If blood pressure increased above 140/90 mmHg antihypertensive treatment was 
initiated or adjusted. 
Blood pressure was measured before the start of sunitinib (baseline) and one week ( 7-11 days; 
week 1) after the start of sunitinib in a quiet room in supine position after a period of at least 5 
minutes rest using an automated device (Welch Allyn Vital Signs 5300P). At two weeks after the 
start of sunitinib blood pressure was measured at the outpatient clinic in sitting position using an 
automated device (Welch Allyn Vital Signs 5300P). 
Blood samples for laboratory measurements were obtained from an intravenous line at baseline 
and week 1, in the morning after an overnight fast in supine position after a period of rest of at 
least 5 minutes. 
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Biochemical measurements
Plasma renin concentration was measured by an immunoradiometric assay (Cisbio), 
aldosterone by radioimmunoassay after extraction with dichloromethane and subsequent 
paper chromatography  and endothelin (ET-1) by chemiluminiscent ELISA (Quantiglo®, R&D 
Systems;intra-assay coefficient of variation 4%).
 
Data analysis
Data are presented as mean±SEM or median and interquartile ranges as appropriate. Statistical 
analysis of blood pressure was performed by one way ANOVA followed by Tukey’s multiple 
comparison testing. Biochemical measurements were analyzed by Wilcoxon rank sum test, 
considering not all values were distributed normally. For correlation analysis the non-parametric 
Spearman coefficient was used. P <0.05 was considered significant.  GraphPad Prism version 
5.03 was used for all statistical analysis. 
5
Vascular effects of angiogenesis inhibitors
80
Results
Twenty mRCC patients signed informed consent and were included in this study. Subjects had a 
median age of 59 years ( range 27-72 years); table 1. One female patient was included. Eleven 
patients were already on antihypertensive medication before the inclusion in the study.  The type 
of antihypertensive medication is shown in table 1. 
TABLE 1 
 Patient characteristics
Patient characteristics Baseline 1 week 2 weeks 
N 20 20 20 
Age (median±range) 59 (27-72) 
BMI (mean±SE) 27.9 ± 1.0 
Hypertensive medication (n) 11 11 11 
Calcium antagonist 5 5 5 
Beta-blocker 4 4 4 
RAAS inhibitor 6 6 6 
Thiazide diuretics 4 4 4 
Diastolic BP >90 and/or  
systolic BP >140 mmHg 
6 10 13 
Blood pressure
Mean arterial  pressure (MAP) before the start of sunitinib was 100.1±2.4 mmHg (mean ± 
SE). After one week of treatment with sunitinib the MAP increased to 104.6±2.0 mmHg (not 
significant). After two weeks of sunitinib treatment MAP significantly increased from baseline to 
110.1±3.4 (p<0.05). At week 2 MAP had increased from baseline by more than 5 mmHg in 13 
patients (65%). Diastolic blood pressure (DBP) increased from 82.1±2.6 mmHg to 86.7±2.4 
at week 1 (not statistically significant) and 93.0±3.2mmHg at week 2 (p<0.05 compared to 
baseline and week 1). Systolic blood pressure (SBP) did not change significantly After 2 weeks 
of treatment in total thirteen patients met the criteria ( SBP > 140 mmHg or DBP > 90 mmHg) 
of hypertension , while all used the same antihypertensive medication as on baseline, except for 
one patient who had an increase in ramipril from 2.5mg to 5mg on day 10 to control hypertension. 
At the outpatient clinic at week 2, after recording of blood pressure, antihypertensive medication 
was changed or started by the treating oncologist to further control hypertension.
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FIGURE 1
 Blood pressure in response to sunitinib treatment *P<0.05 compared to baseline. **P< 0.05 compared to week 1.
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Figure 1 Blood pressure in response to sunitinib treatment. *P<0.05 compared to baseline. ** P< 0.05 compared to week 1.
Biochemical measurements
In 80% of patients aldosterone increased after one week of treatment combined with a decrease 
in renin in also 80% of patients (16/20) (Figure 2). Endothelin was only measured in 15 patients, 
due to missing samples. Endothelin increased in 93% of patients (14/15) (fi gure 2).   
FIGURE 2
Individual values of biochemical measurements before and after 1 week of sunitinib treatment. In the boxes below the 
graphs median and interquartile ranges are depicted. 
Aldosterone (n=20); renin (n=19); endothelin (n=15) *P<0.05 comparend to baseline
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Figure 2. Individual values of biochemical measurements before and after 1 week of sunitinib treatment.
In the boxes below  the graphs median and interquartile ranges are depicted.
Aldosterone (n=20); renine (n=19); endothelin (n=15) * P<0.05 compared to baseline.
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Correlation blood pressure and plasma aldosterone and endothelin 
The rise in aldosterone at week 1 was correlated with the increase in blood pressure from 
baseline (both MAP and DPB) at week 2. This correlation was not found for the rise in endothelin 
and blood pressure (r2= 0.04 ; p=0.88   ). 
FIGURE 3 
Correlation of delta aldosterone (baseline - week 1; n=20) with delta MAP at 2 weeks. Correlation of delta aldosterone 
with blood pressure analyzed in the subgroup of 15 patients, in whom endothelin was measured was also significant 
(P<0.01; r2 =0.77)
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Figure 3. Correlation of delta aldosterone (baseline - week 1; n=20) with delta MAP at 2 weeks.
Correlation of delta aldosterone with blood pressure analyzed in the subgroup of 15 patients,
in whom endothelin was measured  was also significant (P<0.01; rs = 0.77)
p<0.01
rs=0.57
 
Discussion 
We showed, in a sample of 20 patients one week after start of sunitinib a significant rise in 
aldosterone and endothelin. Aldosterone, but not endothelin, was correlated with the subsequent 
increase in blood pressure after two weeks of treatment.
Aldosterone is the major mineralocorticoid, regulating electrolyte balance in the human body. It 
is known that overproduction of this hormone leads to hypertension and cardiac failure(19, 20). 
Two other clinical studies have not shown a rise in aldosterone during treatment with a VEGFR 
inhibitor (13, 21). An important difference between these studies and our study is the timing of 
sampling. We studied the effect on aldosterone after one week of treatment to study the factors 
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involved in the initiation of hypertension, while in the study of Kappers et al. blood samples were 
not taken until week 4, a time point at which hypertension already had occurred. As in our study 
Kappers et al reported a decrease in renin concentration after start of sunitinib. This is also 
supported by Curwen et al who showed a decrease in plasma renin activity in rats exposed to 
a VEGFR-inhibitor(22). This decrease in renin concentration could be caused by an increase in 
aldosterone. The etiology of the observed increase in aldosterone is not easily explained. In mice 
exposed to a VEGF-A antibody a rise in angiotensin II concentrations has been reported(23). 
As angiotensin-II stimulates the production of aldosterone via the angiotensin-II receptor this 
could explain the rise in aldosterone found in our study. However some other studies contradict 
these findings, as ACE-inhibition did not prevent hypertension in animals treated with a VEGFR 
inhibitor (14). Another possible mediator of the increased aldosterone concentration could be an 
increase in ACTH(24) or reduced clearance of aldosterone which in theory, could also result in a 
(transient) increase in aldosterone.
Besides the rise in aldosterone we observed a rise in endothelin after one week of treatment 
with sunitinib. This is in line with the findings of Kappers et al. after four weeks of sunitinib. (13). 
Endothelin-1, a protein produced by vascular endothelial cells, promotes vasoconstriction and 
is increased in hypertension(25, 26) In our study we did not find a correlation between the rise in 
endothelin and the rise in blood pressure.  Therefore,  we postulate that the rise in endothelin is 
secondary to the rise in aldosterone and/or blood pressure and that endothelin sustains rather 
than initiates the increase in blood pressure during sunitinib treatment. Several studies support 
this hypothesis, as aldosterone seems to up regulate endothelin-1 gene expression(27-29). In 
vitro VEGF stimulates the expression of prepro-endotheline-1 and secretion of endothelin-1 in 
human umbilical vein endothelial cells(30). Consequently,  VEGFR-inhibition should decrease 
rather than increase plasma endothelin, as was indeed shown after start of sunitinib  (13). 
Therefore,  our observed increase in endothelin-1 does not seem to be a direct consequence 
of VEGFR inhibition, but should be secondary to other mechanisms such as increased plasma 
levels of aldosterone. 
Finally, some limitations of our research should be mentioned. First, before the start of sunitinib 
already half of the patients included were on antihypertensive medication. Thirty percent of patients 
used an angiotensin converting enzyme inhibitor or an angiotensin-II receptor antagonist, which 
influence aldosterone release.  However apart from the start of sunitinib no other medication was 
started or changed during the study period and blood pressure lowering medication at baseline 
did not prevent the development of hypertension. Furthermore, if anything, this medication 
should have blurred any relation between aldosterone and blood pressure. Therefore co-
medication does not likely explain our observation. Second, non-specific time effects could have 
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confounded our observations. Given the need to start effective standard treatment in patients 
with progressive metastatic disease as soon as possible, it was not considered appropriate 
to perform a placebo controlled study with the first aim of understanding the pathogenesis of 
sunitinib-induced hypertension. Third, unfortunately our sampling method did not allow us to 
measure concentrations of angiotensin, which could have provided more insight into the renin-
angiotensin system. For the same reason it was not possible to measure catecholamines to 
provide insight into the potential involvement of the sympathetic nervous system.
Perspectives
Future investigations could focus on mechanisms of sunitinib-induced aldosterone increase. 
Moreover, in patients treated with sunitinib, the application of aldosterone receptor antagonists 
for the treatment of sunitinib induced hypertension and their potential role in the prevention of 
cardiac damage should be studied. 
 
Conclusion
Aldosterone/renin-ratio significantly increased after one week of sunitinib use, indicating an effect 
of sunitinib on aldosterone exposure. The rise in aldosterone is correlated with the increase in 
blood pressure after two weeks suggesting that aldosterone triggers hypertension in sunitinib-
treated patients. Therefore, antihypertensive medication targeting the aldosterone receptor, such 
as spironolactone, could be an adequate treatment option to prevent or treat  sunitinib-induced 
hypertension and related organ damage. 
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Abstract
Weight loss, cachexia and sarcopenia are profound problems in the frail oncologic patient. With 
the development and increasing use of angiogenesis inhibitors in metastatic cancer patients, 
the question raises what their influence is on body weight and composition. Angiogenesis is 
not only important for the growth, development and metastatic potential of tumors, but also for 
physiologic processes in adipogenesis. A less known approach of angiogenesis inhibitors is 
their experimental use in obese models. This review focuses on the effects on body weight and 
composition of angiogenesis inhibitors, especially of those targeting the vascular endothelial 
growth factor (VEGF) pathway.
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Introduction
Cancer, body weight and body composition are strongly interrelated. Weight loss occurs in 30-
80% of cancer patients, with a severity depending on the type of tumor.[1] Weight loss is the 
result of an imbalance between energy intake and energy expenditure. Factors that contribute 
to decreased intake include anorexia, nausea and vomiting, constipation, diarrhea, pain, altered 
taste and depression. Besides this imbalance, cancer patients are at risk to develop cachexia. 
Cancer cachexia is a profound metabolic process characterized by breakdown of the muscles 
and abnormalities in fat and carbohydrate metabolism despite adequate nutritional intake. This 
debilitating and life-threatening paraneoplastic phenomenon is present in about 50% of cancer 
patients, most markedly in patients with lung or upper gastrointestinal cancers.[2] Furthermore, 
cancer patients are at risk to develop sarcopenia; a severe depletion of skeletal muscle. 
Sarcopenia is related to poor functional status, poor treatment response and reduced overall 
survival.[3;4]
Weight loss in cancer patients can be a direct effect of the disease but also be a side effect of 
treatment. Weight loss indeed is a common side effect of most types of anti cancer therapy.[5-8] 
However, clear insights in the prevalence and amount of weight loss due to the different anti 
cancer therapies are lacking. The degree of weight loss as an adverse event of anti cancer 
therapy can be scored according to the Common Toxicity Criteria Adverse Event (CTCAE criteria)
[9]. These criteria score weight loss in grade 1 to 3, in which grade 1 is defined as 5-10% weight 
loss, without need for an intervention, grade 2 as 10-20% weight loss or nutritional support 
indicated and grade 3 is defined as weight loss of more than 20% compared to baseline body 
weight, or an indication for transparenteral nutrition or tube feeding. In study reports, little attention 
is paid to grade 1 and 2 toxicities. But grade 1 and 2 weight loss may already be substantial 
and clinically relevant, especially in the frail oncologic patient. As little as 5% weight loss alters 
measurable physiological parameters such as immune response, lung and cardiac function 
tests and autonomic autoregulation.[10] The mechanisms by which weight loss occurs during 
chemotherapy are not clear. Of course, anorexia, nausea, vomiting and diarrhea will contribute 
to weight loss during chemotherapy. Both weight loss prior to start as well as weight loss as an 
adverse event of chemotherapy seem to be an indicator for poor prognosis.(1) For example, 
patients with advanced ovarian cancer who suffered from weight loss during chemotherapy had 
a poorer overall survival compared to patients who gained weight.[11] However, not all cancer 
patients treated with chemotherapy lose weight, and some regain weight shortly after finishing 
their chemotherapy. Furthermore, some therapies, especially hormonal therapies, can provoke 
weight gain.[12-14]
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With the development and increasing use of angiogenesis inhibitors, the question raises whether 
these targeted drugs also have such systemic adverse events of weight loss or changes in body 
composition. Angiogenesis is not only important for the growth, development and probability to 
metastasize of tumors, but also for physiologic processes in adipogenesis.[15] A less known, but 
interesting, approach of angiogenesis inhibitors is their (experimental) use in obesity. This review 
focuses on the effects on body weight and composition of angiogenesis inhibitors, especially 
of those targeting the vascular endothelial growth factor (VEGF) pathway. In one way this may 
be an unwanted side effect of anti cancer therapy but in another way it may be regarded as an 
innovative approach for the development of new treatment strategies of obesity. 
Angiogenesis inhibitors and weight loss in cancer
Tumors are dependent on angiogenesis for growth and metastasis. They trigger the development 
of their own blood supply by disrupting the delicate balance of pro angiogenic and anti angiogenic 
factors. Pro-angiogenic gene expression is increased by physiological stimuli, such as hypoxia. 
Oncogene activation or tumor suppressor genes inactivation can tip the balance in favor of pro-
angiogenic factors. Examples of pro angiogenic factors are vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF) and placental growth factor 
(PlGF). VEGF and its receptors play a pivotal role in both normal and malignant angiogenesis. 
Activation of the VEGF pathway leads to endothelial cell activation, proliferation and survival. 
Moreover degradation of the basement membrane is necessary for endothelial cell migration 
and invasion, increased vascular permeability, and mobilization of endothelial progenitor cells 
(EPCs) from the bone marrow into the peripheral circulation.[16] VEGF is expressed in response 
to hypoxia, oncogenes or cytokines. Higher levels of VEGF (among other growth factors and 
cytokines) have been associated with more aggressive tumors, more accentuated weight loss 
and nutritional intake reductions concomitantly with higher resting energy expenditure compared 
to control patients.[17]
The VEGF pathway is considered to be the most important and best explored pathway in 
angiogenesis of tumors. Multiple treatment strategies, targeting VEGF as well as its receptor 
(VEGFR) and downstream signaling elements of this pathway, have been developed. Examples 
are bevacizumab, a monoclonal antibody against VEGF, used for the treatment of metastatic 
colorectal cancer and breast cancer and sunitinib and sorafenib, both VEGFR tyrosine kinase 
inhibitors used predominantly in the treatment of metastatic renal cell cancer.
Less is known about the effect of VEGF tyrosine kinase inhibitors (TKI) on body weight, since 
only severe weight loss is reported according to the CTCAE criteria.(Table 1) Even in case of the 
approved, and frequently applied, VEGFR TKIs (such as  sunitinib, sorafenib and pazopanib), 
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data about weight loss are limited. Weight loss was reported for sorafenib (inhibitor of Raf-
1, B-Raf, VEGFR, PDGFRβ, fms-like TK-3 and c-KIT) compared to placebo in patients with 
metastatic renal cell carcinoma.[18] In this study the sorafenib treated patients experienced 
significantly more diarrhea, without significant differences in nausea and anorexia.(18) Another 
study which combined sorafenib with interferon alpha in patients with metastatic renal cell 
cancer observed all grades weight loss in 63% of the patients.[19] In a placebo controlled trial 
with sorafenib in more than 600 hepatocellular carcinoma patients, significant more weight loss 
in the sorafenib treatment group was observed compared to the placebo.[20] In a phase II 
study of sunitinib (inhibitor of VEGFR1-3, PDGFRα and β, fms-like TK-3, KIT, colony stimulating 
factor receptor type 1 and neurotrophic factor receptor) in non small cell lung cancer (NSCLC), 
anorexia and decreased weight were reported together (gr 1-2: 30%, gr 3: 5%).[21] A phase I 
study which combined sunitinib with bevacizumab reported grade 1-2 weight loss in 12% of 
the participating patients.[22] Other trials using sunitinib did not report weight loss.[23;24]. In 
conclusion, in the majority of trials weight loss was not mentioned. In those trials that did report 
weight loss, the course of the weight loss after finishing study treatment was not mentioned nor 
was the effect of weight loss on quality of life, treatment outcome or prognosis. 
An interesting potential new indication for treatment with a VEGFR inhibitor (especially sorafenib) 
is metastatic medullary, follicular and papillary thyroid cancer. In a phase II study with patients 
with medullary thyroid cancer, grade 1-2 weight loss was reported in 48% of the patients treated 
with sorafenib. [25]Another phase II study in which patients with metastatic papillary thyroid 
cancer were treated with sorafenib reported weight loss grade 1-2 in 58 to 89% of the patients 
and grade 3 weight loss in 5% of the patients.[26] The M.D. Anderson retrospectively reported 
their experience with sorafenib or sunitinib treatment in patients with dedifferentiated thyroid 
cancer. The result for weight loss and anorexia are presented together and were found in 20% 
of the patients.[27] Of further notice is the fact that hypothyroidism, causing weight gain instead 
of weight loss,  is reported as an adverse event of both sorafenib and sunitinib in up to 85% of 
the metastatic renal cell cancer patients, with the requirement of replacement therapy in only a 
minority of them. [28;29] 
To obtain more insights in the time course of weight loss we collected data from four phase I-II 
studies concerning approximately 70 patients who were treated with a tyrosine kinase inhibitor 
against VEGFR1-3. After 2 months of treatment we observed a mean weight reduction of 5.1% 
(range -15.8% to +5.2%), and at the end of study a mean weight reduction of 8.5% (range 
-23.8% to +5.2%). The number of patients who experienced a weight reduction of more than 
5% was 45% after 2 months, and 69% at the end of the study. This significant weight loss was 
usually already present after 2-4 weeks of treatment. The weight loss was more than clinically 
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expected based on the limited number of patients complaining about anorexia, nausea and 
diarrhea complaints. Importantly, after discontinuation of the VEGFR tyrosine kinase inhibitors 
regain of body weight within a couple of weeks was observed. These observations suggest that 
treatment with VEGFR tyrosine kinase inhibitors is associated with disproportionate weight loss.
Apart from weight loss, changes in body composition have recently been reported.[30;31] In 
a subanalysis of the TARGET trial (phase III study comparing sorafenib to placebo in renal cell 
carcinoma patients) a significant loss of weight (-2.1 kg vs +0.8 kg, p<0.01) and skeletal muscle 
(-7.4 cm2 vs -3.1 cm2, p=0.02) was reported in the sorafenib group during the first 6 months of 
treatment. Changes in adipose tissue were similar but not significant (p=0.3).[30] After one year 
treatment with sorafenib, patients had lost 4.2 kg body weight, 12.1cm2 of total muscle area and 
33.1 cm2 of adipose tissue area (p<0.01) as assessed on CT. Baseline sarcopenia was present 
in 52.5% of all patients, including 72% of the patients with a BMI<25 and in 34% of those with 
a BMI>25 kg/m2. Women were more sarcopenic then men (65% and 48% respectively). After 
one year of treatment with sorafenib, 71% of patients (+18.5%) met the criteria for sarcopenia.
(30) Low BMI and sarcopenia were associated with dose limiting toxicity of sorafenib.[31] Tumor 
progression and sorafenib are both potentially related to progressive loss of weight and muscle, 
however when correcting for tumor response on sorafenib treatment, no significant changes 
were found.[30] 
Important adverse events of angiogenesis inhibitors are anorexia, nausea, stomatitis and diarrhea. 
By influencing energy intake and energy expenditure, all these adverse events can cause weight 
loss.[32] However, most of these adverse events are less common reported for angiogesis 
inhibitors compared to conventional chemotherapy. Moreover, edema and hypothyreodism are 
side effects of angiogenesis inhibitors that can contribute to weight gain. Therefore, it is hard to 
belief that only adverse events as anorexia, nausea, stomatitis and diarrhea are the explanation 
for the pronounced weight loss observed in cancer patients treated with angiogenesis inhibitors. 
This suggests that angiogenesis inhibitors may have a direct effect on body weight, beyond side 
effects and anti-tumor effects.
The role of angiogenesis in adipogenesis
Healthy adults have a stable mass of adipose tissue and the supporting vasculature is quiescent.
[33] Adipose tissue can grow and regress during adult life. It has been hypothesized that this 
non-neoplastic adipose tissue growth is dependent on neovascularization.[34] Adipose tissue 
is highly vascularized, with an extensive capillary network nourishing each adipocyte.[35;36] 
Adipose tissue is considered being the largest endocrine gland because it produces free fatty 
acids, hormones, growth factors, and cytokines.[37] Several of these adipose tissue derived 
Metabolic effects of angiogenesis inhibitors
97
products influence angiogenesis, with a delicate balance between pro-angiogenic factors, e.g. 
VEGF, fibroblast growth factor (FGF), IGF, tumor necrosis factor alpha (TNF-α), transforming 
growth factor (TGF-β), EGF, resistin and leptin, and anti-angiogenic factors, e.g. adiponectin, 
endostatin, thrombospondin 1 (TSP-1), and soluble VEGFR2.(15) As is the case in cancer, 
hypoxia in adipose tissue induces high levels of hypoxia-inducible transcription factor (HIF), 
which increase the expression of angiogenesis related factors including VEGF and downregulate 
several endogenous angiogenesis inhibitors.[38-40] A disturbance in this balance, either 
pathophysiologically or due to medical interventions, can cause changes in angiogenesis. 
Compared to lean mice, nutritionally induced or genetically determined ob/ob obese mice have 
significantly larger subcutaneous and gonadal fat pads, accompanied by significantly higher 
blood content, increased total blood vessel volume and a high number of proliferating cells, 
which emphasizes the role of angiogenesis in the process of adipogenesis.[41] In several 
animal studies VEGF is the most important angiogenic factor in adipogenesis and inhibition of 
VEGF is associated with weight loss and metabolic changes. VEGF-A is highly expressed in rat 
adipose tissue and its expression increases significantly during adipocyte differentiation.[42-44] 
In rats, the omentum was found to have the greatest VEGF secretion and the omental adipocytes 
were the primary source of the VEGF. Incubation of omental adipocytes under hypoxic conditions 
induced an increase in VEGF expression.[45] These findings suggest an important connection 
between adipose tissue, VEGF and hypoxia. 
Effects of VEGFR tyrosine kinase inhibitors on adipose tissue and in obesity
In a model with murine adipocytes implanted in dorsal skin chambers treatment with an antibody 
to the VEGFR-2 blocked the development into adipose tissue with inhibition of both angiogenesis 
as well as subsequent vessel remodeling.[46](Table 2) After 7 days of treatment, a significant 
lower vessel density compared to the control group was observed. Vatalanib (PTK787/ZK222584, 
a VEGFR tyrosine kinase inhibitor) treatment for four weeks of mice on a high fat diet resulted in 
a significant reduction of body weight and of subcutaneous and gonadal adipose tissue mass, 
without significant changes in blood vessel size and density.[47] Vatalanib also reduced adipose 
tissue development. No effect of vatalanib on blood glucose and insulin levels was found. In two 
earlier studies with vatalanib in nude mice on standard diet, no decrease in body weight was 
observed.[48;49] A third study, using vatalanib in a murine renal cell carcinoma model showed 
anti tumor activity as well as changes of bodyweight.[50] In another study, two weeks treatment 
with a monoclonal anti-VEGF antibody of db/db mice did not result in a significant difference in 
bodyweight, although the treated mice tended to gain less weight compared to the control group. 
At the cellular level, anti-VEGF treatment markedly inhibited formation of smaller differentiating 
adipocytes as well as formation of blood vessel sprouts and adipogenic/angiogenic cell clusters. 
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Also, the number of adipocytes was significantly reduced.[51] This effect on adipose tissue was 
also noticed in the patients treated with sorafenib for one year in the TARGET trial.[30]
The sarcopenia observed in patients treated with sorafenib may also be associated with the 
inhibition of VEGFR.[30] Inhibition of VEGFR by sorafenib in a variety of cells has been shown to 
result in downstream inhibition of PI3K, AKT, and mammalian target of rapamycin (mTOR). These 
elements are central to the activation of muscle protein synthesis by amino acids and other 
stimuli. The Akt/mTOR pathway is upregulated during hypertrophy and downregulated during 
muscle atrophy.[52;53] Phosphorylation of mTOR also results in the activation of amino acid 
transporters.[52;53] In this way, sorafenib treatment, has a direct inhibitory effect on protein 
synthesis and it limits the stimulating effect of amino acids.[54] Induction of muscle anabolism by 
physical activity occurs by pathways involving RAF, MEK, and MAPK/ERK kinases. This pathway 
is also inhibited by sorafenib.[55] 
Although the observations listed above suggest that inhibition of angiogenesis may reverse 
obesity, angiogenesis inhibitors have not yet been applied to treat human obesity. One of the big 
hurdles to overcome is the observed severe side effect of sarcopenia, as are other frequently 
occurring adverse events which impair chronic use in obese patients. These adverse events 
include cardiovascular disorders[56;57], at which obese people already have an elevated risk. 
Furthermore, drug resistance may develop.[58] At last, knowledge about the long term adverse 
events of angiogenesis inhibitors is lacking. Nevertheless, the findings suggest that further 
research into this area is warranted. 
Conclusion
Both in cancer and obesity, two totally distinct but major health problems, tyrosine kinase 
inhibition can be an important shared target for treatment.
Based on limited data in literature and own findings, we hypothesize that tyrosine kinase inhibitors 
may be an innovative approach for the development of new treatment strategies for obesity, one 
of the biggest threats to human health.  Although the pathophysiological connection between 
angiogenesis and adipogenesis is well recognized, until now, only limited research has focused 
on treatment of obesity with angiogenesis inhibitors. VEGF(R) seems to play a central role in both 
angiogenesis as well as adipogenesis, although other targets of the described  multityrosine 
kinase inhibitors can not be excluded to contribute also to these processes. 
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In case of cancer, weight loss has huge consequences for the frail oncologic patient, not in the 
least on quality of life. It is important to stress that tyrosine kinase inhibitors are more and more 
applied as chronic treatments in cancer patients. Better insights into the severity, the impact and 
the mechanism of weight loss due to angiogenesis inhibitors in cancer patients are essential for 
the development of preventive measures and treatment of this side effect.
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TABLE 1.  
Weight loss as adverse event of tyrosine kinase inhibitors in human studies.
Ref Type of study Target Finding
[18] Sorafenib vs placebo in mRCC 
patients
VEGFR, PDGFRβ, FLT-3, 
c-KIT
Sorafenib induced weight loss (all grades 
10 vs 6%, grade 2; 5 vs 3% (significantly 
different), grade 3-4 <1 and 0%).
[19] Sorafenib and IFN-α in mRCCpa-
tients
VEGFR, PDGFRβ, FLT-3, 
c-KIT
All grades weight loss in 63% of the  
patients, grade 1 weight loss in 37%, grade 
2 in 23% and grade 3 in 3% of the patients. 
[20] Sorafenib vs placebo in HCC patients VEGFR, PDGFRβ, FLT-3, 
c-KIT
Significant more weight loss in sorafenib 
treated patients (all grades: 9% versus 1%, 
and grade 3: 2% versus 0%, respectively). 
[31] Sorafenib in HCC patients VEGFR, PDGFRβ, FLT-3, 
c-KIT
Significant loss of weight and skeletal  
muscle in the sorafenib treated group 
during the first 6-12 months of treatment. . 
Low BMI and sarcopenia were associated 
with dose limiting toxicity of sorafenib. 
[21] Sunitinib in NSCLC patients VEGFR1-3, PDGFRα/β, 
FLT-3, KIT
Anorexia and decreased weight  
(gr 1-2: 30%, gr 3: 5%).
[22] Sunitinib and bevacizumab in pa-
tients with advanced solid cancer
VEGF, VEGFR1-3, PDG-
FRα/β, FLT-3, KIT
Grade 1-2 weight loss in 12% of the  
patients. 
[23] Sunitinib in RCC patients VEGFR1-3, PDGFRα/β, 
FLT-3, KIT
No data on weight loss reported.
[24] Sunitinib vs IFN-α in RCC patients VEGFR1-3, PDGFRα/β, 
FLT-3, KIT
No data on weight loss reported.
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TABLE 2.  
Effects of angiogenesis inhibitors on adipose tissue and in obesity in preclinical studies.
 Ref Type of study Target Finding
[46] Murine adipocytes implanted in dorsal 
skin chambers treatment with an anti-
body to the VEGFR-2
VEGFR2 Inhibition of the development of adipose 
tissue with inhibition of both angiogenesis 
and subsequent vessel remodeling.
[47] Mice treated with valatinib and a high 
fat diet.
VEGFR1-3 Significant reduction of body weight and of 
subcutaneous and gonadal adipose tissue 
mass, without significant changes in blood 
vessel size and density.
[48;49] Nude mice treated with valatinib and 
standard diet
VEGFR1-3 No decrease in body weight.
[50] Murine renal cell carcinoma model 
treated with vatalanib
VEGFR1-3 Anti tumor activity as well as changes of 
bodyweight. 
[51] Monoclonal anti-VEGF antibody in  
db/db mice 
VEGF No significant difference in bodyweight. 
Inhibited formation of smaller differentiat-
ing adipocytes, blood vessel sprouts and 
adipogenic/angiogenic cell clusters. The 
number of adipocytes was significantly 
reduced. 
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CHAPTER 7
The early effect of sunitinib on insulin clearance in  
patients with metastatic renal cell carcinoma
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Abstract
 
Aim
In patients with diabetes treated with sunitinib symptomatic hypoglycemias have been reported. 
To explore the mechanism of this adverse effect we performed a prospective study to investigate 
the effect of sunitinib on insulin concentration, insulin clearance  and insulin sensitivity.
Methods
We studied the early effects of sunitinib on insulin sensitivity and insulin clearance with a 
hyperinsulinemic euglycemic clamp (insulin infusion rate 60 mU . m-2 . min-1; steady state 90-120 
minutes) in patients with renal cell carcinoma before and one week after start of sunitinib 50mg 
per day. Insulin sensitivity index  (SI) was defined as steady-state glucose disposal divided by 
the steady-state plasma insulin. Ten patients (one with diabetes, treated with metformin) were 
included in the study protocol.
Results
Steady-state insulin concentrations during the clamp increased after one week of sunitinib  (from 
128.9 ± 9.0 mU L-1 to 170.8 ± 12.8 mU L-1, p<0.05; 95% CI on difference -64.3 to -19.6). The 
calculated insulin sensitivity index decreased from 0.22± 0.04 before to 0.18 ± 0.02 µmol kg-1. min-1 
. (mE/L)-1 insulin (p<0.05; 95% CI on difference 0.07 to 0.08).  As insulin infusion rate was similar for 
both clamps, the increased steady-state insulin concentration indicates reduced insulin clearance. 
 
Conclusion
Sunitinib affects insulin clearance which could possibly lead to overexposure to insulin in patients 
using insulin or insulin-secretion stimulating agents. 
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Introduction
The development of tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth 
factor (VEGF) have improved cancer treatment, however their use can be hampered by side 
effects. Sunitinib, a VEGFR-TKI, is currently used for the treatment of metastatic renal cell 
carcinoma (mRCC), gastrointestinal stromal cell tumors (GIST) and pancreatic neuroendocrine 
tumors. 
The most reported side effects of sunitinib are hypertension, fatigue, hand-foot syndrome, 
and diarrhea [1, 2]. Several case reports and retrospective studies mention the occurrence of 
hypoglycemia during the treatment with sunitinib in patients with diabetes mellitus treated with 
a sulfonylureum derivate or insulin [3-6]. To explore the mechanism of this adverse effect we 
performed a prospective study to investigate the effect of sunitinib on insulin concentration, 
insulin clearance  and insulin sensitivity.
 
Material and Methods
After approval of the protocol (NCT01227213) by the Institutional Review Board of the Radboud 
university medical center, a total of 10 mRCC patients with a indication to start sunitinib were 
recruited. All participants provided written informed consent. Patients were eligible if they had 
a life expectancy  of more than 12 weeks,  a WHO performance status of 0-2 and no evidence 
of severe or uncontrolled diseases other than renal cell carcinoma. Patients treated with 
corticosteroids or oral anti-coagulants were excluded.  All studies were performed at the Radboud 
university medical center according to institutional and Good Clinical Practice guidelines. In the 
week before and one week (7-10 days) after starting treatment with sunitinib (50 mg/day), a 120 
minutes hyperinsulinemic euglycemic clamp was performed.
The experiments were performed in the morning after an overnight fast. Patients took their 
medication in the morning of the experiment with a cup of water. Subjects were studied in supine 
position in a temperature-controlled room (23-24ºC). Before the start of the experiment blood 
samples were obtained for the measurement of fasting insulin and glucose.  Two intravenous 
cannulae were inserted. One was positioned retrogradely into a dorsal vein of the hand that was 
placed in a plexiglass box, ventilated with heated air, for sampling of arterialized venous blood 
[7]. The second cannula was inserted in an antecubital vein of the contralateral arm for infusion 
of insulin and glucose.  During the clamp insulin (Insulin aspart; Novorapid®; NovoNordisk, 
Bagsvaerd, Denmark; diluted in NaCl 0.9% to a concentration of 1 U ml-1, with the addition of 2 
7
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ml whole blood per 50ml) was infused at a rate of 60mU min-1m-2 body surface area. Arterialized 
venous plasma glucose determinations were performed at 5-min intervals using an enzymatic-
amperometric method (Biosen C-line GP+; EKF-diagnostic GmbH, Barleben, Germany). Plasma 
glucose was clamped at glucose 5.0mmol/L (i.e., 90mg/dL), to reach an euglycemic state, by 
a variable infusion of glucose 20% solution. The validity of the glucose clamp measurements of 
insulin sensitivity depends on achieving steady-state conditions.  The t1/2 of insulin in plasma 
is 4-6 minutes, so after 30 minutes insulin levels already reach steady state, however glucose 
concentration and infusion should also reach steady state with a co-efficient of variation of <5%, 
therefore the period of 90-120 minutes of the clamp is as steady state. At 90 and 120 minutes 
after the start of the clamp, venous blood was sampled and  after centrifugation the supernatant 
was stored at -80°C until the measurement of insulin in all samples of all patients by radio-
immunoassay  at the same time. Plasma insulin was assessed by an in-house radioimmunoassay 
(RIA) using 125I-labeled human insulin and anti-human insulin antiserum raised in guinea pig. 
Bound and free tracer were separated by sheep anti-guinea pig antiserum and precipitation by 
means of polytehylene glycol (PEG). The interassay coefficient of variation (CV) for the insulin 
measurement was 4.7%  and the intra-assay coeffecient of variation was 9.7% at a level of of 34 
mU/l.
 
Statistical Analysis 
 
For calculation of the whole body glucose disposal (M-value) during the euglycemic clamp the 
following formula was used: 
M-value =     x            µmol kg-1 min-1
 
The insulin sensitivity index [µmol kg-1 min-1 (mU L-1) is a measure of insulin sensitivity in relation to 
the plasma insulin concentration during the steady state of the euglycemic clamp[8]. The insulin 
sensitivity index was calculated by dividing the M value by the mean insulin concentration during 
the euglycaemic clamp.
Differences in parameters before and after the start of sunitinib were statistically analysed using 
a parametric Student’s t-test for paired observations.  Data are presented as mean ± SEM. A 
value of P < 0.05 was considered to be statistically significant.
Mean glucose infusion 90-120 min(mg/min)
Weight (kg)
1000
(180 g/mol)
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Results
Baseline characteristics
Between March 2012 and January 2013 ten patients signed informed consent and were included 
in the study.  All patients had mRCC and sunitinib was the choice of treatment as decided by 
their oncologist. Mean age was 59(range 43-72) years. One patient had diabetes and used 
metformin. Sunitinib treatment for one week had no significant effect on fasting glucose, fasting 
insulin, BMI or blood pressure (Table 1). Creatinine increased significantly after start of sunitinib, 
however several studies show that the pharmacokinetics of insulin aspart are not affected by 
impaired renal function[9, 10].
TABLE 1  
Baseline and clamp characteristics
Baseline characteristics (n=10)
Age (mean + range) ( years) 59 (43-72) 
Sex (male/female) 9/1 
BMI (± SE) 27.2 ± 1.1 
Diabetes  (n) 1 (uses metformin) 
Before start sunitib After 1 week of sunitinib
Systolic blood pressure (mmHg) 134.0 ± 3.8 140.5 ± 3.1 
Diastolic blood pressure (mmHg) 80.4 ± 3.5 84.2 ± 3.7 
Glucose (fasting) ( mmol/L) 5.1 ± 0.2 5.0 ± 0.2 
Insulin (fasting) (mU/L) 13.8 ± 1.3 14.1 ± 2.7 
Creatinine (mmol/L) 104.5 ± 10.0 122.2 ± 12.6*
Hyperinsulinemic euglycemic clamp Before start sunitinib After 1 week of sunitinb
Insulin (mU/L) at 90 minutes 127.0  ± 10.2 176.9  ± 13.7*
Insulin (mU/L) at 120 minutes 130.8  ± 8.4 164.7  ± 14.7*
Mean insulin mU/L 128.9  ± 9.0 170.8  ± 12.8*
All data presented as mean ±SE ; * P<0.05 compared to before start of sunitinib.  
Conversion of glucose: mmol/L x 18.02 = mg/dL
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FIGURE 1
Effect of sunitinib on individual insulin concentrations during steady state (90-120 min) of the hyperinsulinemic clamp 
before (baseline) and one week after the start of sunitinib treatment  
*P < 0.02
Insulin sensitivity
During the hyperinsulinemic euglycemic clamp, glucose concentrations were stable but mean 
levels were not completely similar (before 4.84 ± 0.10 mmol L-1 and after one week of sunitinib 
5.06 ± 0.09 mmol L-1, P <0.05). The mean coeffi cient of variation for blood glucose during 
steady state was <5% in both experiments. Sunitinib treatment did not increase whole body 
glucose disposal (M-value) during the clamp (26.5 ± 3.7 µmol kg-1 min-1 before start vs. 28.5 ± 
3.1 µmol kg-1 min-1, P>0.05). 
Mean plasma insulin concentrations (table 1) obtained during the steady state of the clamp were 
signifi cantly higher after one week of sunitinib treatment (128.9 ± 9.0 mU L-1 versus 170.8±12.8 
mU L-1; p<0.02)( 95% CI on difference -64.3 to -19.6) (Figure 1), indicating reduced clearance of 
insulin as insulin was infused at a fi xed rate.  
Before start of sunitinib, the patients were insulin resistant compared to previously studied lean 
healthy volunteers[11], as shown by a calculated insulin sensitivity index of 0.22 ± 0.04 µmol kg-1 
min-1 per mU L-1(95% CI on difference 0.07 to 0.08).   After one week of sunitinib, the calculated 
insulin sensitivity index decreased to 0.18 ± 0.02 µmol kg-1 min-1 per mU L-1 (P <0.05) suggesting 
a decrease in insulin sensitivity.
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Discussion
The present study demonstrates for the first time that sunitinib reduces insulin clearance in 
patients with mRCC. This conclusion is based on the higher steady state insulin concentrations 
during the clamp, where insulin is infused in a fixed infusion rate when subjects were treated with 
sunitinib. 
The mechanism of the reduced insulin clearance during sunitinib treatment is not yet known. 
Insulin clearance is a complex phenomenon and depends on metabolic degradation, which is 
thought to be largely receptor mediated [12, 13].  The liver is the primary site for insulin clearance, 
removing 40-80% during the first portal passage [13]. The first step in insulin clearance is 
binding to its receptor on the cell membrane activating the tyrosine kinase pathway leading 
to internalization of insulin followed by degradation in lysosomes  [14-16] [17]. In vitro studies 
have indicated that insulin internalization and insulin action are linked[18].  Thus insulin-induced 
insulin receptor activation not only mediates insulin actions but is also involved in its  clearance. 
Sunitinib, has shown binding affinity with the insulin receptor and inhibits the insulin like growth 
factor type 1 receptor inducing ubiquitination and thereby degradation of this receptor [19, 
20].  Therefore, it is likely that sunitinib can inhibit the kinase activity of the insulin receptor and 
consequently hamper insulin internalization and degradation. 
Beside the effect on insulin clearance we observed a significant decrease in the calculated 
insulin sensitivity index, suggesting a decline in insulin sensitivity. However comparisons of insulin 
sensitivity during hyperinsulinemic euglycemic clamps are only valid if the same conditions are 
reached for all patients[21]. In our subjects the same insulin infusion rate was used throughout 
the experiment, however insulin concentrations were significantly higher after start of sunitnib and 
moreover glucose clamp levels differed significantly, therefore we cannot draw firm conclusions 
from these measurements regarding insulin sensitivity. It is intriguing that the potential effect of 
sunitinib on insulin sensitivity is congruent with its effect on insulin clearance, supporting the 
notion that both effects are mediated by interaction of sunitinib with the insulin receptor.
Some limitations to our study should be addressed. First, we did not observe an effect of 
sunitinib on fasting blood glucose and fasting insulin. However in our population of patients not 
treated with insulin or SU-derivatives, normal regulation of endogenous insulin secretion must 
have compensated the reduced insulin clearance by reduced pancreatic release of insulin. A 
similar study in patients with diabetes would be interesting to confirm the effect of sunitinib 
on insulin clearance in this population. However this is not feasible considering the size of the 
patient population and the needed sample size . Second, C-peptide concentration, as measure 
7
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of endogenous insulin production, was not measured. Under clamp conditions, C-peptide 
levels as marker of endogenous insulin production are typically  suppressed[22, 23]. Third, 
creatinine increased significantly after start of sunitinib, however several studies show that the 
pharmacokinetics of insulin aspart are not affected by this level of impaired renal function[9, 
10]. Fourth given the need to start active and standard treatment in patients with progressive 
metastatic disease, it was not deemed proportional to perform a placebo controlled study or to 
delay start of treatment to exclude a sequence/time effect with the first aim of understanding the 
cause of reported hypoglycemia.
Conclusion
In summary, one week treatment with sunitinib reduced insulin clearance in patients with 
metastatic renal cell carcinoma. In patients using insulin or insulin-secretion stimulating agents 
the effect of sunitinib on insulin clearance could in theory result in overexposure to insulin and 
thereby induce hypoglycemia. Further research into the effect of sunitinib on insulin levels in 
clinical practice should be performed to see whether the observed effect is of clinical relevance 
to patients. 
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Summary
From the start of 21st century important progression has been made in understanding the 
pathophysiology of cancer. The discovery of several pathways, playing key roles in progression 
and metastatic potential of tumors have led to the development of a new type of drug therapy 
for the treatment of cancer. These new drugs are called targeted therapies, as in contrast 
to chemotherapy they target specific receptors and molecular pathways. One of the key 
pathways involved in tumor growth and spread is angiogenesis, the formation of new vessels. 
Vascular endothelial growth factor (VEGF) plays and important role in this process.  During the 
development of these targeted agents, for example angiogenesis inhibitors, few toxic effects 
were expected as most of these pathways did not seem to play an important role in normal adult 
physiology. However after a decade of treatment with angiogenesis inhibitors in cancer patients 
we have learned that their use can be hampered by specific side effects. 
This thesis focused on the effect of angiogenesis inhibitors on cardiac function, blood 
pressure, body weight and insulin metabolism.
Heart failure is reported as one of the side effects of angiogenesis inhibitors. Patients treated 
with these therapies have an increased risk (RR 2.78) of cardiac dysfunction(1). Especially 
patients with previous coronary artery disease have an increased risk of developing this serious 
adverse effect(2, 3). To get better insight in the eventual causality between the use of angiogenesis 
inhibitors and cardiac failure in Chapter 2 an in vitro experiment is described, studying the effect 
of sunitinib on contractile force, and the effect of recovery after ischemic stimulation of human 
atrial trabeculae.  Human atrial tissue was harvested during the incision of the right auricle during 
extracorporal bypass surgery, which provides a unique opportunity to collect human atrial tissue 
without exposing patients to unwanted risks. After isolation and connection to a force transducer 
in an organ bath contractile force of the human atrial trabeculae was measured under normal 
and ischemic conditions. Sunitinib at low, but relevant, concentrations did not have a direct effect 
on the function of human atrial cardiomyocytes nor did it hamper the recovery in contractile force 
after a period of ischemia. Therefore our experimental data do not support a direct effect of 
sunitinib on cardiac contractile force to cause the sunitinib-associated heart failure. Other actions 
of sunitinib such as structural or functional changes of the coronary vasculature, an increase in 
cardiac afterload by increasing blood pressure or renal toxicity deserve further investigation.
In chapter 3, 4 and 5 the possible mechanisms for the initiation/development of hypertension 
in patients treated with VEGFR inhibitors are explored in various experiments, ranging from 
preclinical research in animals to clinical experiments in healthy volunteers and patients. 
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In chapter 3 the role of vascular endothelial growth factor in maintaining vascular tone in normal 
physiology was studied in thirty-one healthy male volunteers using venous occlusion plethysmography. 
Bevacizumab, a monoclonal antibody directed against VEGF and also known for its ability to cause 
hypertension was infused into the brachial artery, achieving clinically relevant concentrations in 
the forearm, while achieving low systemic exposure. Bevacizumab did not directly affect forearm 
vasodilator tone. However bevacizumab did specifically reduce endothelium-mediated vasodilation, 
proving that circulating VEGF plays a role in maintaining normal endothelial control of vascular tone. 
This study did not elucidate the mechanism of this altered endothelial function. 
To further explore the mechanism of altered endothelial function and to investigate the 
hypothesis that endothelial dysfunction initiates the start of hypertension during VEGF inhibition 
a preclinical and clinical experiment were performed in chapter 4. Sunitinib, a tyrosine kinase 
inhibitor targeting VEGFR and other tyrosine kinases was studied.  After treatment with sunitinib 
or placebo for seven days rats were euthanized and thereafter the mesenteric arteries were 
mounted in a Mulvany wire myograph to assess endothelium-dependent (with acetylcholine) 
and endothelium-independent (with sodiumnitroprusside) vasorelaxation. Sunitinib reduced 
endothelium-dependent vasodilation, but not endothelium-independent vasodilation in this 
experiment.  The difference in endothelium-dependent vasodilation between controls and 
sunitinib-treated animals disappeared in the presence of a nitric oxide antagonist, suggesting an 
effect of sunitinib on nitric oxide availability. In the clinical experiment ten patients with metastatic 
renal cell carcinoma starting first line treatment with sunitinib were included. Before the start 
and one week after the start of sunitinib endothelium-dependent and endothelium-independent 
vasodilation was assessed in the forearm using venous occlusion plethysmography. No changes 
in blood flow were observed, while mean arterial pressure significantly increased within one 
week after start of sunitinib and even more so after two weeks of treatment in these patients. 
In conclusion, in animals exposed to high concentrations of sunitinib endothelium dependent 
vasodilation is reduced, however this endothelial dysfunction does not precede the development 
of hypertension in patients treated with sunitinib. Other factors, such as neurohormonal changes, 
could play a role as trigger for the development of hypertension.
For that reason chapter 5 reports the results of the measurement of aldosterone, renin and 
endothelin concentrations and blood pressure in twenty patients with metastatic renal cell 
carcinoma before and one week after start of sunitinib. Aldosterone and endothelin were 
significantly increased after one week and blood pressure was significantly increased after 
two weeks of treatment. We found the rise in aldosterone after one week, but not endothelin, 
correlated with the increase in blood pressure after two weeks, suggesting that aldosterone is a 
trigger for the development of hypertension in sunitinib treated patients. 
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Chapter 6 and 7 focus on weight loss and insulin metabolism of  angiogenesis inhibitors.  
In chapter 6 the literature concerning the effect of angiogenesis inhibitors on body composition 
and adipogenesis was reviewed. Adipose tissue is highly vascularized and VEGF is the most 
important angiogenic factor in adipogenesis. In preclinical studies angiogenesis inhibitors 
reduce the number of adipocytes, suggesting that inhibition of angiogenesis may reverse 
obesity, however no studies using TKIs to treat obesity in humans exist.  In cancer and obesity, 
both health problems with an increasing prevalence in the population, angiogenesis inhibition 
can be a target for treatment. 
Previous studies describe the occurrence of hypoglycemias and even regression of diabetes 
during treatment with sunitinib, possibly by improving insulin sensitivity. Therefore Chapter 7 
describes the results of a hyperinsulinemic euglycemic clamp in ten patients with metastatic 
renal cell carcinoma before and one week after the start of sunitinib. Although we were not able 
to detect a definite effect of sunitinib on insulin sensitivity, sunitinib reduced insulin clearance as 
shown by an increase in insulin concentrations during the steady state of the hyperinsulinemic 
euglycemic clamp. We did not observe an effect on fasting glucose concentrations, however a 
normal regulation of endogenous insulin secretion must have compensated the effect on insulin 
clearance in our group of patients. In patients with diabetes using insulin or insulin-secretion 
stimulating agents the effect of sunitinib on insulin clearance could result in overexposure to 
insulin and thereby induce hypoglycemia. 
 
General discussion 
In this thesis several adverse effects of angiogenesis inhibitors were investigated. The first part 
of this thesis focused on the mechanisms causing cardiac failure and hypertension during 
angiogenesis inhibition. Hypertension is an adverse effect but also seems to be a biomarker 
for the antitumor effect of several angiogenesis inhibitors, which makes it of special interest 
for research.  As can be concluded from the findings sunitinib-induced rise in blood pressure 
is preceded by an increase in aldosterone concentration. Moreover endothelial dysfunction 
may be a vascular consequence of VEGF-targeted therapies, but it does not  precede the 
hypertension in VEGFR-TKI treated patients. In contrast to the decrease in endothelial function 
by scavenging VEGF in the arterial circulation in healthy volunteers and by exposing animals 
to high concentrations of sunitinib, in patients treated with sunitinib endothelial dysfunction 
did not occur before the development of hypertension. This difference between sunitinib and 
bevacizumab regarding the effect on endothelial function could be explained by the difference 
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in specificity between a solely VEGF scavenging antibody bevacizumab and the less specific 
tyrosine kinase inhibitor sunitinib, which also targets other pathways (such as PDGFR and 
c-KIT). Moreover the effect on endothelial function of bevacizumab was not enough to directly 
alter basal vascular tone, so therefore these observations are not incompatible with the 
conclusions regarding the timing in endothelial dysfunction and the onset of hypertension in 
chapter 4. Since endothelial dysfunction appeared to be a consequence rather than a cause 
of sunitinib-induced hypertension, we studied the early effects of sunitinib on aldosterone and 
endothelin. Aldosterone increased and precedes the development of hypertension as shown by 
the correlation between its increase and the rise in blood pressure. Endothelin also increased 
within one week after start of sunitinib, however this was not correlated with an increase in 
blood pressure. The rise in aldosterone could possibly initiate the release of endothelin-1, as in 
preclinical experiments it has been shown that aldosteron can trigger endothelin production(4, 
5). In contrast VEGF stimulates the secretion of endothelin and therefore a direct effect of 
inhibition of VEGF on the rise in endothelin-1 is not expected(6). This should be investigated 
in further research. The increase in endothelin could explain the sustainment of hypertension, 
while after an initial rise in aldosterone shown in this thesis, aldosterone seems to normalize 
over time as reported at 4 weeks of treatment by Kappers et al.  Regarding heart failure a direct 
effect of sunitinib on contractility of atrial trabeculae was not found, therefore other factors, such 
as altered preload or afterload or changes in microvasculature should be accountable for its 
development. The rise in aldosterone after start of sunitinib could also, besides the onset of 
hypertension, be involved in the development of cardiac failure. Aldosterone can induce the 
development of cardiac failure by inflammation, fibrosis of cardiomyocytes and treatment with 
aldosterone receptor antagonist showed to reduce mortality in patients with chronic heart 
failure(7, 8). Patients with primary hyperaldosteronism (Conn’s disease) have a higher risk for 
development of left ventricular hypertrophy, atrial fibrillation, heart failure, stroke and myocardial 
infarction as compared with matched patients with essential hypertension(9). Hence the use of 
aldosterone receptor antagonists during treatment with angiogenesis inhibitors could provide an 
excellent way of preventing the development of hypertension and heart failure. 
Recent preclinical observations suggest a role for inflammatory cells and VEGF produced 
by these cells in the regulation of blood pressure(10-12). These observations need further 
exploration in humans in-vivo and patients treated with VEGF-targeted therapy provide a window 
of opportunity to do so. 
Furthermore from a literature review in this thesis we can conclude that angiogenesis inhibitors 
affect body composition and adipogenesis. In theory this could even provide therapeutic options 
for the treatment of patients with obesity, however side effects (next to the costs of these drugs), 
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as described in this thesis, will hamper the use of these type of drugs in patients already at risk 
of developing heart failure and hypertension. 
In cancer patients weight loss has huge consequences for quality of life and future research 
should focus on the mechanism of weight loss during treatment with sunitinib to develop 
preventive measures for this toxic effect.
In the last part of this thesis we established that sunitinib affects the clearance of insulin, which 
could explain reported cases of hypoglycemias and remission of diabetes in literature. Based 
on this observation, we advice patients who are treated with insulin or sulfonylureum derivatives 
(which uncouples insulin secretion from glucose concentration) and who start sunitinib to check 
their fasting glucose levels frequently during the first weeks of sunitinib treatment.
 
Future perspectives 
Learning from adverse effects: mechanism and opportunities
The introduction of angiogenesis inhibitors and targeted therapy in general has improved the 
outcome of several types of cancer. However adverse effects sometimes hamper their use. 
Future research in the interesting era of adverse effects  is still warranted to optimize treatment.
For patients with cancer the development of targeted therapies has led to an improvement in 
progression free and overall survival, but also prolonged periods of treatment. In contrast to the 
conventional chemotherapy most of the targeted agents are administered orally in the outpatient 
setting.  With prolonged duration of treatment the importance of toxic effects and their impact on 
quality of life is increasing. Minor adverse effects, as scored by the CTCAE criteria, can become 
a burden if affecting daily life and moreover dose reduction or interruptions can be needed 
possibly leading to a less effective treatment. Furthermore adverse effects can also cause major 
morbidity or even mortality if not recognized or treated in time. Identification of patients who are at 
risk for the development of side effects and the prompt administration of preventive measures or 
treatment is essential in optimizing treatment duration, safety and efficacy of targeted agents in 
cancer treatment. However some of the side effects of targeted therapies, such as hypertension 
in VEGFR targeted therapies, have been shown to be biomarkers of efficacy at least in renal cell 
carcinoma, which makes the approach to the prevention or treatment even more challenging(13).
Another reason to research the adverse effects of targeted therapy in cancer prompts us to 
leave the field of cancer treatment. Adverse effects of targeted therapies in patients with cancer 
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imply that these same pathways have an essential role in normal physiology. Research into the 
role of these pathways in normal physiology can provide insight into the pathogenesis of other 
diseases, such as hypertension or heart failure, and finally it can even open doors to explore 
therapeutic potential of these targeted pathways for the treatment of other diseases, such as 
diabetes, hypertension and obesity. In this regard, the results of this thesis justify future research 
to understand the role of tyrosine kinases in the regulation of insulin clearance and their role as 
a trigger of hypertension and its complications
8
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Nederlandse samenvatting
Vanaf het begin van de 21e eeuw is er een belangrijke vooruitgang geweest in het begrijpen 
van de ontstaanswijze en ontwikkeling van kanker. De ontdekking van verschillende processen 
en signaalwegen die een essentiële rol spelen in de groei en de verspreiding van kankercellen 
heeft geleid tot de ontwikkeling van een nieuw type geneesmiddelen voor de behandeling van 
kanker. Deze nieuwe medicijnen worden doelgerichte behandelingen ( in het Engels ‘targeted 
therapy’) genoemd, omdat ze in tegenstelling tot de klassieke anti-kanker behandeling, gericht 
zijn op specifieke signaalwegen en/of aangrijpingspunten op de kankercel. Chemotherapie 
daarentegen is gericht op alle sneldelende cellen in het lichaam.
Eén van de processen die een belangrijke rol speelt in de groei en verspreiding van kanker 
is het vermogen van kankercellen om de aanmaak van nieuwe bloedvaten (angiogenese) te 
stimuleren. Hierdoor wordt de tumor voorzien van voldoende bouwstoffen en zuurstof. De 
tumor zorgt daarbij voor het vrijkomen van verschillende groeifactoren,  met name de vasculaire 
endotheliale groeifactor (VEGF) die vervolgens aan de vasculaire endotheliale groeifactor 
receptor (VEGFR) bindt. 
Dit proces van bloedvatnieuwvorming werd reeds in de jaren 70 van de vorige eeuw door de 
Amerikaanse onderzoeker Folkman beschreven. Na tientallen jaren van onderzoek werd in 
2004 de eerste doelgerichte behandeling gericht op dit proces geïntroduceerd. Bevacizumab, 
een monoklonaal antilichaam gericht tegen VEGF, werd geregistreerd voor de behandeling 
van darmkanker en was daarmee de eerste remmer van de bloedvatnieuwvorming ofwel 
angiogeneseremmer. Inmiddels wordt bevacizumab ingezet in de behandeling van enkele 
andere soorten kanker en zijn er daarnaast meer dan veertig andere doelgerichte behandelingen 
geregistreerd. 
Toen de angiogeneseremmers net werden geïntroduceerd was de verwachting dat er weinig 
bijwerkingen zouden zijn, omdat de behandeling doelgerichter op de kankercel afgestemd is 
dan bijvoorbeeld chemotherapie. Helaas traden er wel degelijk bijwerkingen op bij patiënten. 
Dit proefschrift bestudeert een aantal van deze bijwerkingen van angiogeneseremmers, te weten 
de effecten op hartfunctie, het ontstaan van hoge bloeddruk, de veranderingen in het gewicht 
en insuline metabolisme.
De geneesmiddelen die worden gebruikt in de beschreven experimenten zijn bevacizumab, 
een monoklonaal antilichaam gericht tegen VEGF, dat via een infuus wordt toegediend, en 
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sunitinib, een angiogeneseremmer in tabletvorm, die behalve gericht tegen VEGF, ook andere 
signaalwegen (zoals PDGF en C-KIT) blokkeert. 
Toegepaste methoden
De belangrijkste methoden die in dit proefschrift gebruikt worden zijn het atriale hartspierweefsel 
model, veneuze occlusie plethysmografie, de mulvany myograaf en de hyperinsulinemische 
euglycemische clamp.
In het atriale hartspierweefsel model (hoofdstuk 1, figuur 1) wordt humaan hartspierweefsel 
verkregen door incisie van het rechter hartoor voor het aansluiten van de hartlongmachine ten 
behoeve van ingrepen, waarbij tijdelijk het hart moet worden stilgelegd en de functie van hart- en 
longen moet worden overgenomen. Dit moment zorgt voor een unieke mogelijkheid om humaan 
hartspierfweefsel te verkrijgen zonder patiënten bloot te stellen aan extra risico’s. Patiënten 
worden vooraf aan de operatie op de polikliniek om toestemming gevraagd. Na isolatie en 
verbinding van de hartspiertjes aan de krachttransducer in een orgaanbad kan de contractiele 
kracht onder normale omstandigheden en tijdens zuurstofgebrek worden gemeten en het effect 
van farmaca hierop worden bestudeerd.
Veneuze occlusie plethysmografie (zie figuur 2 in hoofdstuk 1) is een gevalideerde methode 
om bloeddoorstroming in de onderarm te kunnen meten in rust en in reactie op de toediening 
van verschillende medicijnen die worden toegediend in de slagader in de elleboogsplooi. 
De toediening in de elleboogsslagader zorgt ervoor dat er lokaal hoge concentraties van 
het geneesmiddel kunnen worden bereikt in de onderarm zonder dat de patiënt of gezonde 
vrijwilliger systemisch wordt blootgesteld aan toxische hoeveelheden, omdat na verspreiding 
van het geneesmiddel in het gehele lichaam de uiteindelijke concentratie zeer laag is. Om beide 
bovenarmen wordt een bloeddrukband aangebracht die herhaaldelijk wordt opgepompt tot 
40mmHg om intermitterend kortdurend de bloeduitstroom te belemmeren, maar de instroom te 
behouden. De bloeddoorstroming wordt gemeten met kwik-gevulde bandjes die zeer nauwkeurig 
de toename in omvang, en dus toename van bloeddoorstroming, van de onderarm kunnen 
registreren. Deze bloeddoorstroming in de onderarm reflecteert de vaattonus in weerstandsvaten. 
Door infusie van acetylcholine kan men de endotheel-afhankelijke vaatverwijding meten en met 
sodiumnitroprusside de endotheel-onafhankelijke vaatverwijding.
Bij het gebruik van de mulvany myograaf ( zie figuur 3 in hoofdstuk 1) worden de eigenschappen 
van zeer kleine weerstandsbloedvaatjes (100-400µm) bestudeerd. Deze kleine bloedvaten 
spelen een belangrijke rol in het ontstaan van hoge bloeddruk. Voor dit onderzoek worden deze 
bloedvaatjes vrij geprepareerd uit het vaatstelsel gelegen tussen de darmen van geofferde 
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ratten. Een klein segment van het bloedvat wordt vervolgens op twee draadjes geplaatst die 
zijn verbonden met meetapparatuur die de contractiekracht als reactie op verschillende prikkels 
kan meten. 
In het laatste onderzoek wordt de hyperinsulinemische euglycemische clamp (zie figuur 4 in 
hoofdstuk 1) als methode toegepast. Dit is de gouden standaard voor het meten van insuline 
gevoeligheid in mensen. Bij deze methode wordt de bloedglucose vastgehouden (“clamp”) op 
een bepaalde waarde tijdens toediening van insuline, door de infusie van glucose aan te passen. 
Gedurende het onderzoek dat twee uur duurt, wordt om de vijf minuten bloed afgenomen om 
de bloedglucosewaarde te bepalen en de hoeveelheid glucose-infuus hierop aan te passen. 
Na afloop van het experiment wordt berekend hoeveel glucose moest worden toegediend om 
bij een continue infusie van insuline de bloedglucose op peil te houden. Dit geeft daarmee de 
gevoeligheid van het lichaam voor insuline weer. 
 
Samenvatting van de hoofdstukken
Hartfalen is beschreven als een van de bijwerkingen van angiogeneseremmers. Patiënten 
die worden behandeld met deze medicijnen hebben een verhoogd risico op de ontwikkeling 
van een verminderde hartfunctie. In het bijzonder patiënten met een eerdere vernauwing of 
blokkade in de kransslagaders hebben verhoogde kans op deze ernstige bijwerking. Om beter 
inzicht te krijgen in het verband tussen het gebruik van angiogeneseremmers en hartfalen 
wordt in hoofdstuk 2 een in vitro experiment beschreven, waarbij het effect van sunitinib op 
contractiekracht van hartspierweefsel en het effect op het herstel van deze contractiekracht 
na een periode van zuurstofgebrek wordt gemeten. Sunitinib in lage, maar klinisch relevante, 
concentraties had geen direct effect op de functie van humane atriale hartspiercellen en tevens 
niet op herstel na een periode van zuurstofgebrek. Onze experimentele data ondersteunen niet 
de hypothese dat een direct effect van sunitinib op cardiale contractiekracht de oorzaak is voor 
het ontstaan van hartfalen bij het gebruik van angiogeneseremmers.  Andere mogelijke oorzaken 
van hartfalen veroorzaakt door sunitinib zoals structurele of functionele veranderingen aan het 
coronaire vaatstelsel, een verhoging van de nabelasting van het hart door een verhoging van de 
bloeddruk of nierfalen dienen verder onderzocht te worden.
 
Hoge bloeddruk treedt op in 19% tot 80% van alle patiënten die worden behandeld met een 
angiogeneseremmer. In hoofdstuk 3, 4 en 5 worden mogelijke mechanismen voor het initiëren en 
ontwikkelen van hoge bloeddruk bij patiënten die worden behandeld met angiogeneseremmers 
onderzocht in verschillende experimenten, variërend van preklinisch onderzoek met dieren tot 
klinisch onderzoek met gezonde vrijwilligers en patiënten.
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In hoofdstuk 3 wordt de rol van de vasculaire endotheliale groeifactor (VEGF) op het behouden 
van een normale vaattonus bestudeerd in eenendertig gezonde vrijwilligers met veneuze 
occlusie plethysmografie. Bevacizumab werd toegediend in de slagader in de elleboogsplooi, 
waarbij klinisch relevant concentraties in de onderarm werden bereikt, en lage systemische 
concentraties. Bevacizumab had geen direct effect op de vaattonus in de onderarm. Er werd 
echter wel een specifiek effect gezien op de endotheel-afhankelijke vaatverwijding, daarmee 
bewijzend dat circulerend VEGF een rol speelt in het behouden van een normale endotheliale 
controle van de vaattonus. Deze studie verklaart nog niet het mechanisme achter deze 
verandering in endotheelfunctie.
Om dit mechanisme verder te onderzoeken en om de hypothese te toetsen dat een verstoring 
in de endotheelfunctie het ontstaan van een hoge bloeddruk initieert tijdens de behandeling met 
angiogeneseremmers werd een preklinisch en klinisch experiment uitgevoerd in hoofdstuk 4. 
In dit preklinische experiment werden ratten gedurende zeven dagen behandeld met sunitinib 
of placebo. Na zeven dagen werden de ratten geofferd en de mesenteriale (rondom de 
darmen) bloedvaten werden vrijgeprepareerd en opgehangen in een mulvany myograaf om de 
endotheel afhankelijke ( met acetylcholine) en de endotheel onafhankelijke ( met nitroprusside) 
vaatverwijding te meten. Sunitinib verminderde de endotheel afhankelijk vaatverwijding, maar 
niet de endotheel onafhankelijke vaatverwijding in dit experiment. Het verschil in endotheel 
afhankelijke vaatverwijding tussen de controle groep en de sunitinib behandelde groep verdween 
in de aanwezigheid van een stikstofoxide antagonist. Dit suggereert een effect van sunitinib op 
het stikstofoxide (NO) metabolisme. Stikstofoxide is een vaatverwijder, die normaal gesproken 
via het endotheel wordt vrijgegeven. 
In het klinische experiment werden tien patiënten met recent gediagnosticeerde uitgezaaide 
nierkanker, waarvoor het plan was om te starten met behandeling met sunitinib, geïncludeerd 
in het onderzoek. Voor de start en een week na de start van de behandeling met sunitinib werd 
de endotheel afhankelijke en endotheel onafhankelijke vaatverwijding gemeten met veneuze 
occlusie plethysmografie. Er werden geen veranderingen in bloeddoorstroming geobserveerd, 
terwijl de bloeddruk wel significant steeg na een week behandeling met sunitinib en nog verder 
steeg na twee weken behandeling. 
Concluderend werd in dieren, behandeld met hoge doseringen sunitinib, een vermindering 
gezien van de endotheelfunctie, maar deze verandering in endotheelfunctie gaat niet vooraf 
aan de ontwikkeling van hypertensie in patiënten behandeld met sunitinib. Andere factoren, 
zoals neurohormonale veranderingen, zouden een rol kunnen spelen in het uitlokken van de 
ontwikkeling van hoge bloeddruk. 
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Daarom beschrijft hoofdstuk 5 de resultaten van de meting van aldosteron, renine en endotheline 
concentraties bij twintig patiënten met uitgezaaide nierkanker net voor de start en een week na 
de start met sunitinib. Aldosteron en endotheline waren na een week significant verhoogd en 
de bloeddruk steeg significant na twee weken behandeling. De stijging in aldosteron, maar niet 
de stijging van endotheline, was gecorreleerd met de stijging van bloeddruk na twee weken. 
Dit suggereert dat aldosteron een trigger is voor de ontwikkeling van hypertensie in patiënten 
behandeld met sunitinib.
Hoofdstuk 6 en 7 gaan over het effect van angiogeneseremmers op gewichtsverlies en 
insuline metabolisme.
Hoofdstuk 6 geeft een overzicht van de wetenschappelijke literatuur over het effect van 
angiogeneseremmers op lichaamssamenstelling en de ontwikkeling van vetcellen. Vetweefsel is 
zeer rijk aan bloedvaten en VEGF is de belangrijkste factor in de ontwikkeling van bloedvaten tijdens 
de vorming van nieuw vetweefsel. In preklinische studies verminderen angiogeneseremmers het 
aantal vetcellen, dit zou suggereren dat remming van angiogenese overgewicht zou kunnen 
verminderen. Er zijn echter geen studies met mensen, die angiogeneseremmers met het doel 
om overgewicht te behandelen onderzoeken.
Eerdere studies beschrijven het optreden van hypoglycemieën (te lage bloedsuikers) en zelfs 
vermindering van diabetes gedurende de behandeling met sunitinib. Een van de oorzaken zou 
een verbetering in de gevoeligheid voor insuline kunnen zijn. Daarom worden in hoofdstuk 7 
de resultaten beschreven van een hyperinsulinemische euglycemische clamp bij tien patiënten 
voor- en een week na start van de behandeling met sunitinib. Ondanks dat we geen direct effect 
van sunitinib op insulinegevoeligheid konden detecteren, observeerden we wel een daling in 
de klaring van insuline gedurende de stabiele fase van de clamp. We zagen geen effect op 
de nuchtere glucose concentraties, maar dit kan verklaard worden, omdat de patiënten geen 
diabetes hadden en onder normale omstandigheden een vermindering in afgifte van insuline 
door de alvleesklier het effect van de verminderde insulineklaring zal compenseren. In patiënten 
met diabetes die insuline of insuline-secretie stimulerende medicijnen gebruiken kan het effect 
van sunitinib op de klaring van insuline mogelijk wel leiden tot een verhoogde blootstelling aan 
insuline en daarmee een te sterke daling van de bloedglucose. 
Algemene beschouwing
In dit proefschrift werden verschillende bijwerkingen van angiogeneseremmers onderzocht. De 
eerste twee delen concentreerden zich op de mechanismen achter hartfalen en hypertensie 
tijdens de behandeling. Hypertensie is een bijwerking, maar daarnaast lijkt het ontwikkelen van 
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een hoge bloeddruk ook samen te gaan met het antitumor effect, het is dus een biomarker, 
waardoor onderzoek naar het ontstaan van deze bijwerking extra interessant is.
Uit dit proefschrift kan geconcludeerd worden dat de stijging van de bloeddruk door sunitinib wordt 
voorafgegaan door een stijging in de aldosteron concentratie. Daarnaast is endotheeldysfunctie 
een consequentie van de remming van VEGF, maar gaat het niet vooraf aan het ontwikkelen 
van hypertensie bij remming van de VEGF receptor door verschillende angiogenesremmers. 
In tegenstelling tot de vermindering in endotheelfunctie door het wegvangen van VEGF in de 
arteriële circulatie bij gezonde vrijwilligers en bij het blootstellen van dieren aan hoge doseringen 
sunitinib, zagen we geen verandering in endotheelfunctie bij patiënten met sunitinib vóór het 
optreden van een stijging in de bloeddruk. Het verschil tussen sunitinib en bevacizumab met 
betrekking tot het effect op endotheelfunctie kan wellicht verklaard worden door verschil in 
specificiteit tussen het specifiek wegvangen van VEGF en het minder specifieke effect van 
de tyrosine kinase remmer sunitinib die ook op andere signaalwegen ( zoals PDGF en c-KIT) 
werkzaam is. Daarnaast zagen we ook in de studie met gezonde vrijwilligers dat het effect 
van bevacizumab op de endotheelfunctie niet sterk genoeg was om direct de vaattonus te 
beïnvloeden. De bevindingen in beide onderzoeken zijn dus niet tegenstrijdig met de conclusie 
met betrekking tot de timing van het optreden van endotheeldysfunctie en het optreden van 
hypertensie in hoofdstuk 4. Aangezien endotheeldysfunctie meer een gevolg dan een oorzaak 
van sunitinib-geïnduceerde hypertensie leek te zijn, onderzochten we de vroege effecten van 
sunitinib op aldosteron en endotheline. Aldosteron steeg en ging vooraf aan de ontwikkeling 
van hypertensie. Endotheline steeg ook na een week, echter er was geen relatie tussen de 
stijging en het ontstaan van hypertensie. De stijging in aldosteron kan mogelijk het vrijkomen van 
endotheline stimuleren, zoals in andere preklinische onderzoeken werd geobserveerd. Andere 
onderzoekers hebben beschreven dat VEGF de productie van endotheline juist stimuleert, 
dus dat een direct effect van de remming van VEGF op de stijging van endotheline niet is te 
verwachten. Dit zou verder onderzocht moeten worden. De stijging van endotheline kan het 
persisteren van de hoge bloeddruk verklaren, aangezien aldosteron na een initiële stijging zoals 
beschreven in dit proefschrift, na enkele weken normaliseert zoals beschreven in het onderzoek 
door Kappers et al. 
Met betrekking tot hartfalen werd er geen direct effect van sunitinib op de contractiliteit van 
hartspierweefsel van de hartboezem geobserveerd. Andere factoren zoals een veranderde 
voor- of nabelasting van het hart of een verandering in de kleine bloedvaatjes moeten daarom 
verantwoordelijk zijn voor het ontstaan van hartfalen. De stijging in aldosteron na de start van 
sunitinib kan, behalve bij de initiatie van hypertensie, ook betrokken zijn bij de ontwikkeling 
van hartfalen. Eerdere onderzoeken laten namelijk zien dat aldosteron hartfalen kan induceren 
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door inflammatie en fibrose van hartspiercellen en behandeling met een aldosteron receptor 
antagonist laat een daling van de mortaliteit zien in patiënten met chronisch hartfalen. Daarnaast 
hebben patiënten met primair hyperaldosteronisme ( ziekte van Conn) een hoger risico op 
ontwikkelen van linker ventrikel hypertrofie, boezemfibrilleren, hartfalen en een myocardinfarct in 
vergelijking met patiënten met essentiële hypertensie. Derhalve kan het gebruik van aldosteron 
receptor antagonisten tijdens de behandeling met angiogeneseremmers mogelijk een goede 
manier zijn om de ontwikkeling van hypertensie en hartfalen te voorkomen.
Verder concluderen we uit literatuuronderzoek dat angiogeneseremmers een effect hebben op 
lichaamssamenstelling en de ontwikkeling van vetweefsel. In theorie zou die zelfs mogelijkheden 
bieden voor de behandeling van patiënten met obesitas, echter de bijwerkingen, zoals 
beschreven in dit proefschrift, maar ook de hoge kosten, beperken de mogelijkheid van gebruik 
van deze medicijnen bij een groep patiënten met vooraf al een verhoogd risico op hartfalen en 
hypertensie.
In patiënten met kanker heeft gewichtsverlies gevolgen voor de kwaliteit van leven en verder 
onderzoek zal zich moeten richten op de het mechanisme en de preventie van gewichtsverlies 
tijdens de behandeling met sunitinib.
In het laatste gedeelte van dit proefschrift beschrijven we dat sunitinib de klaring van insuline 
beïnvloedt, wat een verklaring biedt voor de in de literatuur beschreven hypoglycemieën en 
vermindering in insuline behoefte bij nierkanker patiënten met diabetes tijdens de behandeling 
met sunitinib. 
Toekomstperspectieven
Leren van bijwerkingen: mechanismen en mogelijkheden
De introductie van angiogeneseremmers en andere doelgerichte behandelingen heeft de 
prognose van verschillende soorten kanker verbeterd. Het gebruik wordt echter soms beperkt 
door de bijwerkingen. Toekomstig onderzoek naar de verschillende bijwerkingen is nog steeds 
noodzakelijk om de behandeling te optimaliseren.
Voor patiënten met kanker heeft de ontwikkeling van doelgerichte behandelingen geleid tot 
een verbetering in de progressievrije en algehele overleving, maar ook langere periodes van 
behandeling. In contrast tot de conventionele chemotherapie worden de meeste doelgerichte 
behandelingen oraal in de poliklinische setting gegeven. Met een verlengde behandelperiode 
wordt de impact van bijwerkingen op de kwaliteit van het leven groter. Milde bijwerkingen kunnen 
een last worden als ze het dagelijks leven beïnvloeden en soms zijn daardoor dosisaanpassingen 
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of onderbrekingen van de behandeling nodig, waardoor de behandeling ook mogelijk minder 
effectief wordt. Verder kunnen bijwerkingen leiden tot ernstige morbiditeit of zelfs mortaliteit als 
ze niet tijdig herkend of behandeld worden. Herkenning van patiënten die een verhoogd risico 
hebben op het ontwikkelen van bijwerkingen en het tijdig inzetten van preventieve maatregelen 
of behandeling is essentieel in het optimaliseren van behandelduur, veiligheid en effectiviteit van 
doelgerichte behandelingen van kanker. Echter kunnen sommige bijwerkingen, zoals hypertensie 
tijdens angiogeneseremming, ook dienen als biomarker voor het effect van de behandeling,  wat 
de preventie en behandeling van deze bijwerking nog uitdagender maakt.
Een andere reden om onderzoek te doen naar bijwerkingen van doelgerichte behandelingen ligt 
niet binnen het gebied van kankerbehandeling. Bijwerkingen van doelgerichte behandelingen 
bij patiënten met kanker impliceren dat dezelfde signaalwegen ook binnen de fysiologie een rol 
moeten spelen. Onderzoek naar de rol van deze signaalwegen in de normale lichaamsfuncties 
kan inzicht geven in het ontstaan van andere ziektes, zoals hoge bloeddruk en hartfalen, 
en uiteindelijk zelfs deuren openen naar potentieel gebruik van dezelfde signaalwegen voor 
de behandeling van andere ziektes, zoals diabetes, hypertensie en overgewicht. In dit 
kader rechtvaardigen de resultaten van dit proefschrift verder onderzoek naar de rol van de 
verschillende signaalwegen in de regulatie van insuline en hun effect op hoge bloeddruk en de 
bijbehorende complicaties. 
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Bedankt!
Zoals de omslag van dit proefschrift weergeeft lijkt de totstandkoming van dit boekje op een 
routekaart, die gaandeweg werd gevormd, met verschillende paden, soms afwijkend van de 
oorspronkelijke route, daarmee leidend tot nieuwe ideeën of eindpunten, soms enkel dienend 
als olifantenpaadjes om het einddoel niet uit het oog te verliezen. Al deze wegen dragen bij aan 
het eindresultaat.
In dit dankwoord wil ik stilstaan bij de mensen die met mij de wegen van dit proefschrift hebben 
bewandeld. Sommige mensen zijn meegegaan van begin tot eind, bij anderen hebben onze 
wegen elkaar gekruist of zijn we tijdelijk langs de zelfde paden getrokken. 
Als eerste wil ik mijn dank uitspreken aan alle patiënten die mee hebben gedaan aan dit 
onderzoek. In moeilijke en onzekere tijden, hebben jullie deelgenomen aan dit onderzoek, 
waar ik ontzettend dankbaar voor ben. De gesprekken, die we voerden tijdens de ochtenden 
van de experimenten, hebben veel indruk op me gemaakt en me meer inzicht gegeven in de 
belevingswereld van patiënten.
Daarnaast veel dank aan de gezonde vrijwilligers die deel hebben genomen aan het 
onderzoek.
Prof. Rongen, beste Gerard, bedankt voor jouw enthousiasme en passie voor de wetenschap. 
Tijdens mijn promotieonderzoek heb je me laten zien hoe onderzoeksresultaten altijd weer leiden 
tot nieuwe mogelijkheden voor onderzoek. En zo kreeg de weg waarop we gestart zijn met dit 
onderzoek veel zijwegen, soms leidend tot een nieuw eindpunt, soms toch weer terugkerend op 
de weg, als het enthousiasme groter bleek dan de haalbaarheid. Tijdens mijn onderzoek heb ik 
je leren kennen als een creatief onderzoeker, een toegewijde promotor ( het beoordelen van de 
stukken ging soms zo snel dat mijn eufore gevoel dat iets ‘af’ was, binnen een dag verdwenen 
was..), toegewijd aan zijn motor, geïnteresseerd in gadgets en onverstoorbaar tijdens zijn 
werkzaamheden. Je hebt me altijd op verschillende manieren weer weten te motiveren om het 
uiteindelijke doel te bereiken. 
Prof. van der Graaf, beste Winette, bedankt voor je begeleiding tijdens mijn promotietraject. 
Je kritische beoordeling zorgde altijd voor een verfrissende kijk op het onderzoek, waardoor er 
echt de puntjes op de i werden gezet.
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Mijn copromotor dr. van Herpen, beste Carla, naast alles over klinisch onderzoek binnen de 
oncologie, heb ik ook veel van je geleerd over de behandeling van nierkanker. Al leken onze 
wegen soms meer te kruisen dan parallel te lopen, ze bleken toch bij hetzelfde einddoel samen 
te komen. Bedankt voor je begeleiding en het delen van je visie. 
Graag wil ik ook Prof. dr. Paul Smits bedanken, die helemaal aan het begin van dit traject mij 
de mogelijkheid heeft gegeven om te starten met dit onderzoek. 
Beste medeauteurs, jullie hebben allemaal bijgedragen om de kaart te vervolmaken, bedankt 
daarvoor. Een aantal wil ik hier nog apart noemen. Prof. dr. C. Tack, beste Cees, bedankt 
voor je kritische blik en wetenschappelijke kennis met betrekking tot de clamps en de glucose 
stofwisseling. Beste dr. J.Deinum, beste Jaap, bedankt voor het delen van je waardevolle 
kennis over onder andere het RAAS systeem. Beste dr. Desar, Ingrid, ik heb bewondering voor 
jouw doelgerichtheid en efficiëntie. 
De leden van de manuscriptcommissie, Prof. dr. J.W. Smit, Prof. dr. E. Voest en dr. A. van 
den Meiracker, wil ik bedanken voor het beoordelen van dit proefschrift.
Beste collegae promovendi bij de Farmacologie-Toxicologie, velen van jullie gingen me voor 
en anderen zullen nog volgen. Bedankt voor de gezellige tijd en het delen van ervaringen en 
praktische tips ( en de wekelijkse AGIKO besprekingen, CRF’s, SOP’s etc.). 
Beste analisten bij de Farmacologie-Toxicologie, lounge en toren, bedankt voor al jullie hulp en 
uitvoering van de experimenten. Jeanne en Vivienne, bedankt voor de praktische uitvoer van 
de experimenten met de ratten. Helaas verliepen de experimenten lang niet altijd zoals gewenst 
en is de ene rat zeker de andere niet, al zijn ze allemaal wit (of geel?). Italiaanse kaas blijkt toch 
anders te zijn dan Nederlandse. Bedankt voor jullie geduld en het meedenken over oplossingen. 
Annemieke, Fons en Vivienne, bedankt voor jullie werk met betrekking tot de hartoortjes-
experimenten. De onvoorspelbaarheid van de timing van de operaties maakten de planning 
vaak tot een uitdaging. Bedankt Fons dat je de (‘vrije’) tijd hebt genomen om een deel van deze 
experimenten te verrichten. Petra, bedankt voor een oplossing voor de onoplosbaarheid van 
weer een geel stofje en voor de metingen van mijn –ibje. Ab, bedankt voor de gecentrifugeerde 
koffie en het me tijdig voorzien van gunpowder of andere soorten thee als ik daaraan toe was. 
Daarnaast wil ik jullie, ook als kamergenoten, bedanken voor de gezelligheid en de nodige 
ontspanning op zijn tijd. 
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Oncologen, fellows & onderzoekers, verpleging en ondersteunend personeel van de 
Medische Oncologie, bedankt voor al het advies, ondersteuning en de gezelligheid 
tijdens de onderzoeksperiode en opleiding. Dank aan het onderzoeksteam (artsen en 
researchverpleegkundigen) voor de begeleiding en behandeling van de patiënten in de klinische 
studie.
Beste Anja, Karin, Marielle en Evertine en de andere medewerkers op het CRCN, bedankt 
voor jullie hulp en de gezellige tijd tijdens de uitvoering van de experimenten op de klinische 
fysiologie en later op het CRCN. 
Graag wil ik de afdeling Urologie bedanken voor de hulp bij de inclusie van de patiënten in de 
SUMAVA studie. 
De afdeling Cardio-thoracale Chirurgie bedankt voor de mogelijkheid om patiënten te 
includeren in de hartoortjesstudie en voor het verkrijgen van het hartspierweefsel tijdens de 
operaties. 
De basis voor mijn interesse in de oncologie en het onderzoek werden gelegd in het Jeroen 
Bosch Ziekenhuis, waar ik in de eerste jaren van mijn opleiding met veel plezier heb gewerkt. 
Daarom wil ik alle AIOS interne geneeskunde en internisten aldaar bedanken voor de fijne tijd. In 
het bijzonder wil ik Dr. Netten, Paetrick, bedanken voor het enthousiasme, dat hij als opleider 
perfect wist over te brengen.
Ook in het Radboudumc wil ik graag de opleiders, van zowel de interne geneeskunde, klinische 
farmacologie en medische oncologie bedanken, met name ook voor jullie flexibiliteit. De vele 
zijwegen, zoals onderzoek, zwangerschapsverlof, parttime werken en de combinatie van twee 
differentiaties maakten mijn opleidingsschema tot een ingewikkelde routekaart. Prof.dr. J. de 
Graaf, beste Jacqueline, bedankt voor het meedenken over oplossingen en alle correspondentie 
aan de MSRC. 
Beste collega’s in het Catharina Ziekenhuis. Dank jullie wel voor de samenwerking en de steun 
tijdens het afronden van mijn proefschrift. 
Beste paranimfen, Lieve Pleun, uiteraard sta je vandaag naast mij. Als er iemand is die parallel 
met mij de wegen leidend tot dit proefschrift heeft bewandeld ben jij het wel. Samen ANIOS, samen 
AIOS, samen onderzoeker en samen carpoolen en nu ook samen in dezelfde regio internist. Wat 
fijn dat we dit nu ook samen kunnen afronden. En wat gezellig dat we binnenkort elkaar op 
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de fiets kunnen opzoeken. Lieve Saloua, tijdens onze gezamenlijke tijd bij de farmacologie-
toxciologie hebben we heel wat lief en leed, en koffie, gedeeld. Maar ook de dierentuin en je 
optreden als prinses maken dat ik blij ben dat jij mijn paranimf wil zijn. 
Lieve familie en vrienden, bedankt voor al jullie geduld en steun de afgelopen jaren. Nu is het 
af en kunnen jullie lezen waar ik me de afgelopen jaren mee heb bezig gehouden. 
Papa en mama, ik hou van jullie, door jullie steun en vertrouwen ben ik geworden wie ik ben. 
Fijn dat ik bij jullie altijd nog ‘thuis’ ben. Bedankt voor jullie ondersteuning, zelfs in Frankrijk, bij 
de afronding van dit proefschrift. Mama, bedankt voor het altijd luisterende oor, een dagelijks 
terugkerend ritueel, op weg naar huis. Papa, wat fijn om te merken hoe trots je op me bent. 
Lieve Hub, grote broer, het discussiëren hebben we vroeger veel geoefend en dat heeft vast 
bijgedragen tot mijn interesse voor het kritisch beschouwen van informatie. Wat leuk dat we 
na het afronden van onze opleidingen nu weer zo dicht bij elkaar wonen. Superleuk om de 
zondagmiddagen samen door te brengen met jou, Xenia en Sander, terwijl onze kinderen 
samen spelen. 
Lieve Noor en Maud, lieve meisjes, eindelijk het boekje van mama is af. Samen met het maken 
van dit boekje werden jullie de afgelopen jaren steeds groter. Wat is het heerlijk om jullie te zien 
opgroeien en wat is het fijn om bij jullie thuis te komen na een drukke dag werken. 
Lieve Sander, eindelijk, de laatste woorden van dit boekje zijn voor jou. Zonder jou was het zeker 
nooit gelukt, bedankt voor al je liefde, praktische hulp, relativeringsvermogen en je tomeloze 
energie. Met het afronden van dit proefschrift hebben we hopelijk ook weer meer tijd voor elkaar, 
laten we vooral doorgaan met samen genieten van het leven. 
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Annemarie Thijs werd geboren op 5 oktober 1979 te Maastricht. Ze behaalde haar VWO-
diploma in 1997 aan het Stedelijk Gymnasium te Breda. Na een jaar in Honduras op het Liceo 
Catolico Cristo Rey in Siguatepeque begon ze in 1998 aan haar opleiding Geneeskunde aan de 
Universiteit Maastricht en behaalde in 2004 cum laude haar artsexamen. Na haar artsexamen 
werkte ze een half jaar als arts-assistent op de afdeling interne geneeskunde in het Amphia 
ziekenhuis te Breda. In 2005 werd ze aangenomen voor de opleiding interne geneeskunde in het 
Radboudumc te Nijmegen onder supervisie van (prof. Dr. J.W.M van der Meer en Prof. Dr. J. de 
Graaf en later prof. dr.J.W.A. Smit). Van 2005 tot 2008 werkte zij als AIOS interne geneeskunde in 
het Jeroen Bosch Ziekenhuis in ’s-Hertogenbosch (opleider: dr. P. Netten). Daarna zette zij haar 
opleiding voort in het Radboudumc. In 2009 onderbrak zij haar opleiding om aan het onderzoek 
te werken, dat in dit proefschrift beschreven staat, dit onder begeleiding van prof. Dr. Winette 
van der Graaf (Radboudumc, Medische Oncologie), prof. Dr. Gerard Rongen ( Radboudumc, 
Farmacologie-Toxicologie) en dr. Carla van Herpen (Radboudumc, Medische Oncologie). In 
de periode van 2009 tot 2015 werd dit onderzoek afgewisseld met de opleiding tot internist 
en tevens de differentiatie Medische Oncologie en de differentiatie Klinische Farmacologie. In 
februari 2015 werd haar opleiding tot internist-klinisch farmacoloog afgerond en in september 
2015 volgde tevens de registratie tot internist-oncoloog. Na voltooiing van haar specialisatie 
werkt zij vanaf 1 oktober 2015 als internist in het Catharina ziekenhuis in Eindhoven. 
Tijdens haar onderzoeksperiode ontving zij voor het onderzoek beschreven in hoofdstuk 3 
van dit proefschrift een prijs voor het beste abstract op de Internistendagen 2012, de Takeda-
Gert van Montfrans hypertensieprijs 2013 van het Nederlands Hypertensie Genootschap en de 
NVKFB (Nederlandse vereniging voor Klinische Farmacologie en Biofarmacie) TOP-publicatie 
prijs 2014. Voor hoofdstuk 4 kreeg ze de prijs voor best poster EACPT (European Association of 
Clinical Pharmacology and Therapeutics) 2013 in Geneve, Zwitserland. En voor het onderzoek 
beschreven in hoofdstuk 7 van dit proefschrift ontving zij een ESMO (European Society of 
Medical Oncology) travel grant 2014. 
Annemarie woont samen met Sander van de Waarsenburg. Samen hebben zij twee kinderen, 
Noor (2007) en Maud (2010).
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